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Abstract 
Platelets have well-established roles in haemostasis, and this requires a fine balance to 
maintain platelets in a resting state in the absence of vessel injury and allow rapid 
activation upon stimulation. Platelet hyperactivity is associated with several serious health 
conditions such as Acute Coronary Syndrome (ACS), Venous thromboembolism (VTE) 
Myocardial Infarction and Stroke, and so anti-platelet therapies are a critical tool in the 
management of such diseases.  
This thesis evaluated the use of six thienopyridine compounds to modulate platelet activity. 
Members of the thienopyridine family are currently in clinical use in the UK but the variable 
response to specific drugs and the associated side effects warrant continued identification 
and refinement of alternative compounds. 
The work demonstrated that these six novel thienopyridine derivatives were able to inhibit 
ADP-induced platelet activation (assessed by CD62P expression, PAC1 binding and platelet-
leukocyte aggregate formation) and aggregation (assessed by light-transmission 
aggregometry) in platelets obtained from healthy participants. Furthermore, the 
compounds seemed to show enhanced activity when compared with the standard 
thienopyridine, clopidogrel (active metabolite). The signalling pathways affected by these 
compounds were studied and found that Ca2+ flux was affected in ADP-stimulated platelets 
and VASP phosphorylation was maintained. The effects on PLCγ2, cPLA2 and PI3k/Akt were 
variable and inconsistent. 
As endothelial cells also have a crucial role in haemostasis and prevention of inappropriate 
clot formation, and have been shown to be responsive to ADP, this thesis also evaluated 
the effect of the compounds on endothelial cells adhesion molecule expression. All six 
compounds were shown to inhibit CD62P, CD62E and VCAM-1 in stimulated HUVEC cells, 
suggesting a new area for drug development. 
Finally, the thesis shifted focus on to the role of platelets in immunological responses. Since 
platelets have been reported to have central roles in cancer development and to sequester 
proteins from within the microenvironment, the final part of the work looked at whether 
platelet function can be affected by the tumour cell secretome and attempted to 
characterise the cytokines responsible for the effects. The results showed that the tumour 
cell secretome can inhibit platelet activation and aggregation and provides a mechanism 
by which to explain increased bleeding tendency in cancer patients. 
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Chapter 1 : Introduction 
 
Platelets have a well-established role in haemostasis and thrombus formation (Dorsam and 
Kunapuil, 2004). Although this process is tightly regulated, hyperactivity/heightened 
sensitivity of platelets, as well as hypoactivity can occur, and results in inappropriate 
thrombus formation or bleeding tendency respectively (Key et al., 2009). Hyperactivity of 
platelets contributes to myocardial infarction and stroke, two of the most common causes 
of morbidity in the developed world (Zetterberg and Svensson, 2016). The ability to control 
platelet activity and reduce adverse thrombus formation is therefore a critical tool in 
modern clinical practice.  
 
1.1  Platelet biology 
Platelets are enucleated cellular fragments that play an important role in thrombosis and 
haemostasis. These cells are produced by fragmentation of the megakaryocyte cytoplasm, 
where each megakaryocyte produces approximately 1000-5000 platelets (Hoffbrand et al., 
2011). The normal circulating concentration of platelets in healthy individuals is 150-440 
×109/L (McKenzie, 1996). Platelets normally flow in the blood in a dormant (inactive) state 
but respond rapidly to vessel damage by activation and aggregation at the site of injury in 
order to stop bleeding. Platelets express a number of cell surface receptors and contain a 
vast array of proteins that allow them to achieve such quick activation and aggregation. 
Changes to the expression of these receptors or intercellular proteins may lead to a hypo- 
or hyper-active state resulting in excessive bleeding or inappropriate thrombosis 
respectively (McKenzie, 1996; Hoffbrand et al., 2006). 
 21 
1.2  Platelet structure 
Platelets have a discoid shape and are extremely small in comparison to red blood cells, 
with a diameter of 2-3μm (Fig 1.1). The platelet membrane is complex and constitutes 
proteins and lipids, both of which are important in platelet haemostatic function (Fritsma, 
2015). The protein component of the platelet membrane comprises the Glycocalyx that 
coats the platelet surface and is essential for platelet extracellular signaling (Hoffbrand et 
al., 2011). The glycocalyx consists of different glycoproteins such as glycoproteins Ia (GPIa) 
that bind collagen, glycoprotein Ib and IIb/IIIa (αIIb,β3) which bind Von Willbrand factor 
(VWF) and αIIb,β3,  which is a specific receptor for fibrinogen. The middle layer of the 
membrane is composed of phospholipid, which forms the basic structure of platelets, and 
supports platelet activation by supplying arachidonic acid. It has a role in the activation of 
coagulation factor X and Prothrombin (FII). The inner layer of the plasma membrane 
invaginates into the platelet and translates signals from the surface to the platelet’s sub-
structure through the surface connected cannicular system (SCCS), allowing activation of 
the platelet following appropriate stimuli. The Dense tubular system (DTS) works in parallel 
to SCCS sequestering Ca2+ and some enzymes that are involved in platelet activation such 
as phospholipase A2, Cyclooxygenase and TXA2 synthesis (Gresele et al., 2012;  'Platelet 
Structure and Function', 2015). 
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1.2.1 Platelet granules 
There are three different types of storage granules present in platelets; α-, dense- and 
lysosome-granules (Hoffbrand et al., 2011; Ware et al., 2013). Recently presence of a fourth 
granule type has been proposed, referred to as the T-granule (Morrell et al., 2014; Thon et 
al., 2012). The characteristics of the granules are depicted in the Table 1.1 
  
Figure 1.1 Platelet Structure. Platelets comprise membranous components (plasma membrane, 
surface-connected canalicular system, and dense tubular system), mitochondria, microtubules, 
and glycogen, in addition to storage organelles: α-granules, dense bodies and lysosomes 
(Adapted from, Hoffbrand et al., 2011). 
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Granule Number 
per platelet 
Size (nm) Contents  
Alpha 50-80 200-
400 
Heparin agonist, platelet factor 4 
(PF4), platelet derived growth 
factor (PDGF), β-thromboglobulin, 
fibrinogen, von willebrand factor 
(VWF), coagulation factors 
Promote vascular 
repair 
Dense 2-7 150 Adenosine Diphosphate (ADP), 
Adenosine Triphosphate (ATP), 
Ca2+, 5-hydroxytryptapmin 
Recruitment of 
additional platelets 
to site of injury. 
Consequently, 
platelet shape 
change and platelet 
aggregate. 
Lysosome granules 1-3 Unknown Glycohydrolase enzymes and 
catalase 
Degrade the 
material that engulf 
by phagocytosis. 
T-granules Unknown Unknown toll-like receptor (TLR) Platelet recognition 
of invading 
microbes 
 
1.3 Platelet activation  
Platelets are Ca2+normally in a resting state when in the peripheral circulation but they 
become activated at the site of vascular damage following exposure to adhesive proteins 
on endothelial cells, such as collagen and VWF, or by triggering from other platelet agonists 
such as ADP, Thrombin or TXA2 (Li et al., 2010). Upon binding of the agonist to the platelet 
and consequent platelet activation, platelets reorganize the cytoskeleton to change from a 
Table 1-1 Characteristics of platelet granules. Table complied from data from (Hoffbrand et al., 2011; 
Morrell et al., 2014) 
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discoid shape to increase the surface area for adhesion to the immobilized surface. This 
leads to a change in morphology, extending filopodia and eventually lamelliopodia which 
play a role in strengthening the adhesion to injured vessels and other platelets (Aslan et al., 
2012). Moreover, platelet granules also release their contents into the microenvironment 
to exacerbate platelet aggregation and adhesion (Fritsma, 2015). 
 
1.4 Platelets Agonist receptors  
Platelets have an array of receptors on their surface, which can be categorized in to 
adhesion receptors, G-Protein Coupled receptors (GPCR) and Immunoreceptor tyrosin-
based activation motif (ITAM) receptors.  
 
Collagen and VWF are exposed on the sub-endothelium at the site of the damaged vessel 
wall (Fig. 1.2) (Clemetson, 2011). VWF captures fast flowing platelets at the site of injury 
and binds to GPI-V-IX receptors on platelets under high shear conditions (Bergmeier et al., 
2006; Li et al., 2010; Bye et al., 2016). This complex of VWF: GPI-V-IX also induces platelet 
activation and plays a role in stable platelet adhesion and aggregation (Bye et al., 2016). 
VWF also facilitates the interaction between a captured platelet and collagen where it binds 
to α2β1 and GPVI on the  platelet surface, which leads to stable adhesion, initiation and 
activation of platelet signalling (Clemetson, 2011; Bye et al., 2016). Once platelets are 
activated via collagen or VWF, they synthesise secondary mediators including TXA2 via 
cyclooxygenase-1 activity and release ADP from their dense granules. These mediators 
amplify platelet responses and activate the coagulation pathway (Clemetson, 2011). ADP 
binds to P2Y1 and P2Y12 receptors, while TXA2 interacts with TP receptors (Fig. 1.2). 
Activation of P2Y1 and TP receptors leads to an increase in intracellular Ca2+  levels, while 
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inhibiting adenyl cyclase, causing suppression of the formation of cyclic adeonosin 
momophosphate (cAMP) (Li et al., 2010). Consequently, platelet activation and 
responsiveness increase due to these changes.  
 
One of the important proteins at the site of injury that is involved in adhesion is tissue 
factor (TF). TF plays a crucial role in platelet activation of the coagulation cascade and the 
end point formation of thrombin from prothrombin (Clemetson, 2011). Thrombin itself is a 
platelet activator and stimulator of platelet aggregation through protease activated 
receptor (PAR-1 and PAR-4) on the platelet surface. In addition, thrombin plays a role in 
the stabilizing thrombus by activation of fibrinogen to fibrin mesh (Bye et al., 2016).  
 
1.5 Platelet signalling. 
Platelet signalling involves a complex network of G-protein-coupled receptors, numerous 
G-proteins and downstream protein kinases, all of which act to stimulate Ca2+ signalling 
which leads to platelet shape change, release of platelet granule contents and change in 
expression of adhesion molecules (Stalker et al. 2012). The central regulators include 
various phospholipase C isoforms (including PLCβ and PLCγ2), protein kinase C (PKC) and 
phosphatidylinositide-3-kinase (PI3K) (Fig. 1.2) (Bye et al., 2016; Stalker et al., 2012). 
 
The principal signaling events that occur following stimulation with the main platelet 
agonists ADP, collagen, thrombin and thromboxane are shown in Figure 1.2. Although it 
was at one time assumed that there were distinct signaling pathways that became 
activated in response to a given agonist, evidence demonstrates the extensive crosstalk 
and interplay that occurs to ultimately produce a platelet response (Stalker et al. 2012).   
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1.5.1 Platelet signalling via PLC isoforms. 
It has been shown that platelets without PLC cannot be stimulated nor show a Ca2+ flux in 
response to an agonist (Yang et al., 1996). PLC has two isoforms, PLC-γ2 and PLC-β, with 
distinct downstream signaling events. Activation of PLCβ occurs by Gq-coupled GPCR such 
as TP (TXA2’s receptor), P2Y1 (ADP’s receptor) and PAR-1 and PAR-4 (thrombin’s 
receptors). It is important in platelet signaling and is involved in secretion of secondary 
mediators from platelet granules such as ADP and TXA2. PLCβ catalyses the reaction of 
phosphatidylinositol 4,5biphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3). DAG leads to activation of PKC, and IP3 activates the Ca2+ flux into the 
platelet cytosol by binding of IP3 to its receptor on the dense tubular system (DTS) (Szumilo 
Figure 1.2 Stimulation of platelets by various agonists and their major signalling events. The key 
regulatory components of signalling involve PLC, PI3K and PKC which lead to platelet secretion of 
secondary mediators (ADP and TxA2) that work as positive feedback in platelet activation and amplify 
the aggregation. P2Y12 antagonists and GPIIb/IIIa work against these receptors to supress their 
activation by ADP and Fibrinogen respectively. Figure adapted from Bye et al., 2016; McFadyen et al., 
2018). 
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and Rahden-Staron, 2008; Williams, 1999; Bye et al., 2016). Deleting the Gq gene in mice 
was shown to prevent activation of PLCβ leading to platelets unresponsive to thrombin, 
ADP and TXA2. Consequently, inactivated PLCβ lead to impaired, Ca2+ release and PKC 
activation (Nonne et al., 2005).  
 
PLC-γ2 activation is widely associated with the interaction of VWF and GPIb-IX-V, or 
collagen with GPVI. GPVI is one immunoglobulin superfamily that is a platelet specific 
receptor, bearing an ITAM fragment crystallisable (Fc) γ-chain receptor (Nieswandt and 
Watson, 2003). The signaling downstream of PLC-γ2 is complex and requires contribution 
from a number of tyrosine kinases including linker activated T cell (LAT), which itself is 
activated by Syk, which is downstream of Scr family kinase (Bye et al., 2016). PLC-γ2 
activation requires a binding SLP76 with LAT through DAG, to allow Btk to allow 
phosphorylation of PLC-γ2 (Bye et al., 2016). The activation of PLC- γ2 (and other tyrosine 
kinases) is summarised in Fig 1.3. 
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The binding of collagen and fibrinogen to their respective integrins α2β1 and αIIbβ3 can 
also activate PLC-γ2, and presence of LAT in this pathway is not required (Asselin et al., 
1997; Z. Y. Li et al., 2010; Bye et al., 2016). A third pathway of activating PLC-γ2 is by the 
binding of ADP to P2Y12, which in turn results in Gi-PI3K-Rab1b complexing and plays 
crucial role in platelet activation (Nonne et al., 2005). To highlight the crucial role of this 
phospholipase in platelet activation, deletion of PLC-γ2 in a mouse model was shown to 
abolish thrombus formation upon vessel injury (Nonne et al., 2005). 
 
1.5.3 Platelet signalling via PKC. 
PKC consists of a family of isoforms that play crucial roles in platelet intracellular signaling. 
These isoforms have been divided into three different kinds according to their mechanism 
Figure 1.3 Detailed signaling events following stimulation with various agonists (adapted from Li et al, 
2010). 
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and structure. Classical PKC (cPKC) which requires DAG and Ca2+ for its activation, novel PKC 
(nPKC) which is activated by DAG without need for Ca2+ and the third type is typical PKC 
(tPKC) which is insensitive to DAG and Ca2+ for activation. There is still some controversy 
surrounding some PKC isoforms in platelet activation (Z. Li et al., 2010).  
 
PKCδ is a novel PKC important in platelets, where it acts to trigger activation of MEK/ERK 
and p38 MAPK signalling. This leads to the subsequent release of thromboxane A2, which 
is essential for collagen-induced, but not thrombin-induced platelet activation and 
aggregation (Yacoub et al., 2006). A broad spectrum of studies that use PKC inhibitors or 
mice deficient in individual PKC isoforms, have demonstrated that PKC isoforms have 
positive effects on platelet granule secretion, integrin activation, synthesis of TXA2, 
aggregation and thrombus formation (Harper and Poole, 2010). However, some isoforms 
of PKC appear to have negative effects on platelet activation, but this concept is 
controversial (Nishikawa et al., 1980; Harper and Poole, 2010; Unsworth et al., 2011; Poole 
et al., 2004).  
 
1.5.4 PI3K regulatory protein 
PI3K has a role in sustaining platelet activation and providing stablisation of the thrombus 
plug. PI3K class I isoforms phosphorylate PIP2 to produce phosphatidylinositol 3,4,5-
triphosphate (PIP3) which leads to recruitment of proteins with a Pleckstrin Homology (PH) 
domain to the plasma membrane, where they come in close proximity to the downstream 
signaling proteins (Bye et al., 2016). Moreover, PI3K has a minor role downstream of GPVI 
(collagen receptor) on the activity of extracellular signal-regulated kinase (ERK). It has also 
a role on the colocalization of Btk and its substrate PLCγ2 at the plasma membrane (Bobe 
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et al., 2001). PI3Kγ is predominantly involved in downstream signaling of P2Y12 (ADP 
receptor) but has a semi-redundant effect with PI3Kβ which is downstream of GPCR.  
 
1.6 Conditions resulting in platelet hyperactivity  
An abnormal increase of platelet activation is seen in a variety of conditions such as 
cardiovascular disease, diabetes, hyperglycemia and also inflammatory diseases such as 
atherosclerosis (Lukasik et al., 2010). The development of atherosclerosis begins with 
formation of fatty plaque. The rate of atherosclerosis varies among individuals and is 
influenced by a variety of different factors such, both genetic and environmental. 
Unhealthy diet, smoking, drinking alcohol, diabetes in tandem with low exercise can lead 
to increased cholesterol in the blood, which in turn contributes to plaque formation. 
Indeed, obesity plays important role in atherosclerosis progression (Howard et al., 1998; 
Goff et al., 2014). When a plaque ruptures, it exposes thrombogenic proteins such as 
collagen and VWF, which leads to activation and aggregation of platelets to the vessel wall 
and growth of the thrombus (Virmani et al., 1999; Clark et al., 2015). This can lead to 
development of Acute Coronary Syndromes (ACS), a group of conditions used to describe 
acute myocardial ischemia which occurs due to formation of a thrombus at a high-risk site 
leading to an increased risk of MI and stroke. If ACS is not treated quickly, the conditions 
can lead to death. Indeed, ACS is one of the top five causes of death in the UK (Charles River 
Associates, 2011). Platelet hyperactivity plays a critical role in the development of ACS. 
Drugs to reduce platelet activity in such patients are an important pharmacological tool 
(Laine et al., 2016) thereby reducing the risk of activation by the increasingly thrombogenic 
stimuli. 
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1.7  Antiplatelet therapy: 
Inhibiting platelet activity and function in ACS patients may help in stopping the 
reoccurrence of thrombus formation at the site of the plaque. Although initiation of 
platelet activation occurs by collagen, VWF and thrombin as subendothelial matrix 
agonists, ADP is critical as a secondary positive feedback, following its release from platelet 
dense granules (Murugappa and Kunapuli, 2006). Therefore, ADP receptor (specifically 
P2Y12) inhibitors are the most direct treatment approach. 
However, a number of other approaches to inhibiting platelet therapy are under 
development and are mainly targeted at the αIIb/β3. The formation of platelet thrombi is 
determined by the integrin αIIb/β3-mediated interactions of platelets with fibrinogen and 
fibrin. The importance of αIIb/β3 can be seen in patients with Glanzman thrombasthenia, 
which is caused by mutation of αIIb/β3 - patients show severely reduced or absent platelet 
aggregation (Kannan and Saxena, 2009). Table 1.2 provides a brief overview of these 
approaches. Since P2Y12 inhibition is the focus of the present work, these compounds are 
not discussed further in this thesis.  
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Compound Drug Type Target Evidence of benefit 
Abciximab Chimeric 
human Murin 
antibody 
αIIb/β3 
antagonist 
EPIC and EPILOG trials show patients on 
abciximab, heparin and Aspirin have a 35%  
reduction in death, MI and ischemic events in 
comparison with aspirin or heparin only. 
EPISTENT trial showed the benefit of using 
abciximab in patient with coronary stenting – 
reduction in MI and also reduced in bleeding in 
the abciximab arm. 
Eptifibatide Heptapeptide Binds 
reversibly to 
β3 on αIIb/β3 
PURSUIT trial demonstrated only a 1.5% 
absolute reduction in the incidence of the 
primary end point (death or MI) when 
compared to placebo. 
IMAPCT II trial comparing low dose and high 
dose eptifibatide with placebo, showed no 
significant difference in rates of death/MI between 
high dose and placebo, while low dose treatment 
reduced end-point rates from 11.6% to 9.2%. 
Tirofiban Nonpeptide 
derivative 
αIIb/β3 
inhibitor 
RESTORE trial involved patients undergoing PCI and 
have had MI or unstable angina. Tirofiban was 
found to protect against early adverse cardiac 
events related to thrombotic closure, when 
compared with placebo. At 30 days however, the 
reduction in adverse cardiac events was no longer 
statistically significant. 
 
Table 1-2 Novel anti-platelet compounds under investigation 
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1.7.1 Aspirin 
Aspirin or acetylsalicylic acid (ASA), is derived from salicylic acid which is found in the bark 
of the willow tree. Acetylsalicylic acid has been widely used as an anti-inflammatory, anti-
pyretic and anti-thrombotic where it acts to block prostanoid production, a group 
of  eicosanoids which include the prostaglandins, thromboxanes and the prostacyclins 
(Antman et al., 2005). Prostanoid production depends on the activity of the two isoforms 
of the cyclooxygenase (COX) enzymes within cells: COX-1, which is present in most cells and 
its expression is generally constitutive, and COX-2, for which, in platelets, is expressed at 
low levels but is increased massively upon platelet activation. Upon contact of the platelet 
with collagen in the sub-endothelial surface, GPVI receptor signalling leads to release of 
arachidonic acid (AA) by phospholipase A2 (PLA2). This, in turn leads to COX-1 signaling 
which leads to production of prostaglandin G2 (PGG2), prostaglandin H2 (PGH2) and finally 
TXA2 (Smith, 1992). TXA2 is released from activated platelets and binds to its TP receptor  
on the platelet surface for secondary activation. Aspirin irreversibly binds to 
cyclooxygenase-1, ultimately leading to TXA2 inhibition (Loll et al., 1995; Warner et al., 
2010). Ingested aspirin is quickly absorbed from the intestine into blood where it reaches 
peak levels after one hour (Patrono et al., 2004). Then it is cleared from the blood 
circulation after it has been metabolised by the liver within 2 hours (Michelson, 2013) 
. Due to the anucleate nature of platelets aspirin limits the ability for platelets to generate 
new COX-1. Therefore, aspirin inhibitory action remains for the life span (7-12 days) of the 
platelet (Burch et al., 1978). However, normal thrombopoietic turnover in humans means 
that approx. 10% of the circulating platelets every day have been newly released from the 
bone marrow, which can be a limiting factor in cardiovascular patients. Drug dosing 
regimens are critical in ensuring continued effects (Di Minno et al., 1983). Further 
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limitations of aspirin (particularly at high doses); include side effects such as nausea, gastric 
ulcer and bleeding (Serebruany et al., 2005), and in rarer cases renal toxicity (The SALT 
Collaborative (Group, 1991). Lower doses of aspirin can also lead to gastrointestinal 
bleeding. Despite this, aspirin is used often as a first line antiplatelet treatment for ACS 
patients, MI and unstable angina.  
 
1.7.2 ADP receptor antagonists 
As mentioned previously, ADP binds to two different receptors on the platelet surface, 
P2Y12 and P2Y1. The initial response to ADP occurs via P2Y1, which induces platelet shape 
change and Ca2+ mobilization. The P2Y12 receptor is the predominant receptor involved in 
the ADP-stimulated activation of the glycoprotein IIb/IIIa receptor. Activation of the 
glycoprotein IIb/IIIa receptor results in enhanced platelet degranulation and thromboxane 
production, and prolonged platelet aggregation (Hechler et al., 2005). ADP also enhances 
secretion of other material from platelet granules such as P-selectin that plays a role in 
leukocyte intereaction (Wijeyeratne and Heptinstall, 2011). 
 
The importance of ADP in platelet function via its receptors P2Y1 and P2Y12 highlights a 
role for these two receptors as targets for antithrombotic drugs. However, the P2Y1 
receptor is not platelet specific, expressed in many tissues in the body, which reduces the 
feasibility of using it as a target for antithrombotic agents (Wijeyeratne and Heptinstall, 
2011). Thus, P2Y12 is the main focus of anti-platelet drug discovery. 
 
P2Y12 inhibitors consist of two types of drugs; theinopyridines (ticlopidine, clopidogrel, 
prasugrel) and the nucleoside-nucleotide agents (cangrelor, ticagrelor, and Elinogrel) 
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(McFadyen et al., 2018). Theinopyridine drugs are a prodrug which require metabolism 
by liver cytochrome CYP450 (P450) to be active, and they bind to P2Y12 irreversibly 
(Kowalczyk et al., 2009; McFadyen et al., 2018). However, the other group of P2Y12 
inhibitors bind directly to P2Y12 and do not need to be metabolised by P450) (McFadyen 
et al., 2018). 
 
Ticlopidine 
It is first drug become available to inhibit P2Y12. It is orally administrated and requires 
activation by cytochrome P450 (Farid et al., 2007). However, this drug proved to have many 
limitations including hepatic toxicity, thrombotic thrombocytopenic purpura and aplastic 
anaemia (Steinhubl et al., 1999; Wijeyeratne and Heptinstall, 2011). Moreover, many 
patients experienced less severe but nevertheless unwated side effects, such as nausea, 
diarrhoea and vomiting (Michelson, 2013). Therefore, this treatment was phased out and 
replaced by  another thienopyrine family member clopidogrel.  
 
 Clopidogrel 
Like ticlopidine, clopidogrel binds irreversibly to the P2Y12 receptor to inhibit its effect 
when stimulated with ADP (Farid et al., 2010). Although the side effects of this drug were 
shown to be less severe than ticlopidine, symptoms such as gastrointestinal bleeding have 
been reported. Clopidogrel has been tested for its safety against aspirin for preventing 
cardiovascular diseases. The CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of 
Ischemic Event) trial recruited 19000 patients with cardiovascular disease. The results 
showed that clopidogrel was more effective than aspirin in reducing ischemic stroke, 
myocardial infraction, vascular death and bleeding (Lancet, 1996). Since then clinical trials 
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have been conducted involving dual antiplatelet therapy of aspirin in combination with 
clopidogrel. The CHARIMA trial compared use of this duel therapy against aspririn alone 
and although it showed benefit in some patients, overall it was reported that aspirin and 
clopidogrel was not significantly more effective than aspirin alone in reducing the rate of 
myocardial infarction, stroke, or death from cardiovascular causes (Bhatt et al., 2006). In 
contrast, the CURE trial demonstrated beneficial effects of duel therapy in patients with 
ACS without ST-segment elevation. However, the risk of major bleeding was increased 
among patients treated with clopidogrel (Mehta et al., 2001). 
 
With regard to clopidogrel dosing, the CURRENT-OASIS 7 and CREDO trials demonstrated 
that high doses of clopidogrel have beneficial effects in preventing ischemic events, when 
compared to low doses. However, high doses are associated with increased bleeding 
tendency, while low doses are associated with continued platelet hyperactivity (Mehta, 
2010). Despite its relative success, it is reported that 4-30% of patients show no or poor 
response to clopidogrel (Clark et al., 2015). 
 
There are several factors that can influence the effectiveness of clopidogrel. The major 
factor is CYP2C19*2 loss of function allele, resulting in impaired metabolism of the 
compound (Johnson et al., 2012; Clark et al., 2015). P2Y12 receptor gene polymorphisms 
have also been noted (Bouman et al., 2010). Patients with specific comorbidities such as 
diabetes mellitus, intestinal conditions and impaired renal function will also show reduced 
response to the drug (Gremmel et al., 2011; Massarelli et al., 2011; Damman et al., 2012). 
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Prasugrel 
The third generation of oral thienopyridine, prasurgrel irreversibly binds to P2Y12. 
Compared to clopidogrel, prasugrel has a rapid onset of action, blocking the P2Y12 
receptor, and reaching maximum concentration in the blood after approximately 30 
minutes of oral administration. It is also metabolised by cytochrome P450 in the liver 
(Sugidachi et al., 2007; Michelson et al., 2009). Results from the TRITON-TIMI38 trial 
demonstrated that prasugrel (P<0.001) is more effective than clopidogrel in reducing 
ischemic events and myocardial infarction. However, high risk of bleeding was noted in 
elderly patients (>75 years) with history of stroke (Wiviott et al., 2007). Results from the 
JUMBO-TIMI study found significantly more bleeding events in patients taking Prasugrel 
compared to patients taking Clopidogrel (Damman et al., 2012; Sarafoff et al., 2012). 
Interestingly however, in a randomized trial Kim et al. (2016) found that prasugrel 
overcame the poor outcome for the CYP2C19*2 loss-of-function allele seen when treated 
with Clopidogrel (Kim et al., 2016).  
 
Despite the development of prasurgrel, clopigorel and aspirin still remain the mainstay of 
treatment in the UK for patients at risk of thrombotic events. 
 
Cangrelor 
Cangrelor was the first of the direct reversible P2Y12 inhibitors, administrated 
intravenously (Storey et al., 2001). Cangrelor is from the ATP analogue family and has a 
very short half-life of 3-6 minutes. As a result, normal platelet function is restored after 1 
hour of discontinuing the treatment (Storey et al., 2001; Angiolillo et al., 2012). This is 
extremely useful in cases where bleeding begins to occur, and the clinician needs to rapidly 
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reverse the effects. However, a phase III trial showed that cangrelor does not provide 
superiority in terms of primary end-point, MI or ischemic driven revascularization 
compared to clpidogrel (Harrington et al., 2009; Bhatt, 2009). In contrast, the CHAMPION 
PHONIX trial reported benefits of cangrelor in reducing ischemic events without major 
bleeding (D. L. Bhatt et al., 2013). 
 
Ticagrelor 
Ticagrelor (AZD6140) was the first orally administered reversible P2Y12 inhibitor to be 
developed (Kowalczyk et al., 2009). The PLATO trial reported a decrease in thrombotic 
events for patients treated with ticagrelor compared with clopidogrel (Wallentin et al., 
2009). However, ticagrelor has been associated with a higher bleeding risk than clopidogrel, 
but reduced bleeding risk compared with cangrelor and prasugrel (Damman et al., 2012).  
 
Elinogrel  
Similarly to ticagrelor, elinogrel is a direct reversible P2Y12 inhibitor with rapid onset of 
action (Cattaneo and Podda, 2010). Although well tolerated in trials involving healthy 
participants, and demonstration of strong anti-platelet activity, the ERASE-MI randomized 
trial evaluating safety and tolerability of intravenous elinogrel (10, 20, 40, and 60 mg) 
before PCI in patients with STEMI, showed no differences in serious adverse events, 
laboratory values, corrected thrombolysis in Myocardial Infarction frame count, or ST 
resolution when compared with those parameters observed in placebo-treated patients. 
Furthermore, the INNOVATE-PCI trial, comparing eliogrel and clopidogrel treatments in 
patients undergoing non-urgent (including elective) PCI found no difference  in efficacy or 
bleeding tendency at the 24-hour and 120-day time points. However, eliongrel was shown 
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to achieve platelet inhibiton more quickly than clopidogrel.  Despite this, development of 
the drug was terminated in 2012 (Müller et al., 2012). An overview of the P2Y12 inhibitors 
can be seen in table 1.3.
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*Initial dose: clopidogrel 300-600 mg, parasugrel 60 mg,and ticagrelor 180 mg
  Table 1-3 Current P2Y12 inhibitors and their properties. 
P2Y12 
Inhibitor 
Type Administration prodrug Type of 
binding 
Dosage Initiation time of drug Clearance time of the drug 
Ticlopidine  Thienopyridine Oral Yes Irreversible 2x 250 mg 3-5 days 4-5 days 
Clopidogrel Thienopyridine Oral Yes Irreversible 75mg* 3-4 hours 7 days 
Parasugrel Thienopyridine Oral Yes Irreversible 10mg 1-2 hours 7 days 
Ticagrelor CPTP Oral No Reversible 2x90mg* 1-2 hours 5 days 
Cangrelor ATP analogue Intravenous  No Reversible 30μg/kg bolous 
and 4μg/kg/min 
infusion 
15-30 min 1 hour 
Elinogrel Sulphonyle 
derivative  
Oral and 
intravenous  
No Reversible 60mg orally 
Oral: 50–150mg 
Intravenous: 80 or 
120 mg bolus 
twice daily 
 
Not characterized yet. 12 h 
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1.8 Multifaceted roles of platelets 
1.8.1  The role of platelets in inflammation and immunity 
The role of platelets in haemostasis has long been understood. However, recently, there 
is growing appreciation that platelets also function in immune and inflammatory 
processes (Morrell et al., 2014). Platelets are able to recruit leukocytes to the site of 
vascular damage and inflammation by releasing pro-inflammatory mediators such as 
PDGF, PF4 and transforming growth factor –β (TGF-β) (Freedman, 2003; Smyth et al., 
2009). Furthermore, platelets also have the ability to bind to leukocyte receptor P-
selectin glycoprotein ligand-1 (PSGL-1) via interaction with CD62P (P-Selectin) on the 
platelet surface, forming platelet-leukocyte aggregates. In-vivo work has demonstrated 
the importance of these platelet–leukocyte aggregates in vascular disease, as infusion 
of recombinant human PSGL-1 in an animal model of vascular injury reduced myocardial 
reperfusion injury and preserved vascular endothelial function (Freedman, 2003). 
CD62P also acts as an initiator for the complement system, thereby playing a pivotal role 
in orchestrating phagocytosis of invading pathogens (Smyth et al., 2009).  
 
ADP released by dense granules upon platelet activation, binds to the P2Y12 receptor 
on dendritic cells (DCP2Y12), leading to increased antigen endocytosis (Morrell et al., 
2014). Collectively, the literature shows that in addition to the major roles in 
haemostasis, many granule-derived molecules also have secondary functions in 
immunological processes. A summary of granules’ exocytosis and their role in 
inflammatory and immune system in table 1.4. 
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Storage vesicle Molecule Immune/Inflammatory role 
α-granule PF4 Chemokine: monocyte, neutrophil, and T-cell 
recruitment, macrophage phagocytic activity.  
P-selectin Selecting: leukocyte adhesion, complement activation.  
CD40L  TNF superfamily: antigen-presenting cell activation. 
TGF-β Cytokine: cell proliferation, T-cell differentiation, B-cell 
and macrophage phenotype regulation. 
PDGF Growth factor: cell growth and differentiation, 
monocyte/macrophage differentiation. 
VWF Platelet adhesion, PMN extravasation. 
CD63 Tetraspanin: transmembrane adaptor protein, 
leukocyte recruitment.  
SDF-1 Chemokine: T-cell, monocyte, and PMN chemotaxis.  
VEGF Growth factor: angiogenesis, adhesion molecule 
expression. 
Thrombospondins Apoptosis, endothelial cell inflammation, macrophage-
platelet aggregates.  
MIP-1α Cytokine: neutrophil and eosinophil activation, B-cell 
immunoglobulin production.  
MMP-2, MMP-9 Protease: extracellular matrix breakdown, platelet-
leukocyte aggregate formation 
Cyclophilin A Vascular smooth muscle cell growth factor. 
  
Dense Granule Serotonin DC and T-cell functions. 
Glutamate T-cell trafficking 
Polyphosphates Inflammatory response amplification 
ADP Platelet, leukocyte, endothelial cell activation.  
Histamine Increased vessel reactivity and degranulation. 
Table 1-4 List of important platelet-derived inflammatory and immune mediators (Morrell et al., 
2014). 
 38 
  
Produced or 
constitutively 
expressed 
IL-1β Cytokine: acute phase response, leukocyte and 
endothelial activation. 
Thromboxane Eicosanoid: T-cell differentiation, monocyte activation. 
Nitric oxide Reactive oxygen species: anti-inflammatory and 
antithrombotic. 
GPIbα Adhesion molecule: binds Mac-1 on leukocytes. 
 
1.8.2 The role of platelets in malignancy 
Platelets contain more than 30 angiogenesis proteins that may contribute to the 
promotion of new blood vessel growth, particularly in the developing tumour. These 
include Vascular Endothelial Growth Factor (VEGF), Basic Fibroblast Growth Factor 
(bFGF), PDGF, Epidermal Growth Factor (EGF) and matrix metalloproteinase (MMPs) 
(Italiano et al., 2008)  the most important of these in angiogenesis is VEGF. However, 
platelets also contain anti-angiogenic factors such as PF4, endostatin and 
Thrombospodin-1 (TSP-1) (Bambace and Holmes, 2011). 
 
Cancer cells themselves may express or secrete platelet agonists such as Tissue Factor 
(TF), ADP and thrombin. This promotes adhesion of platelets to the tumour cells and 
consequent activation of the platelets. This activation leads to the release of pro and 
anti-angiogenic proteins from the platelets. The mechanism of each angiogenic factor is 
illustrated below (Daly et al., 2003).  
 
It has been reported that there is a direct relationship between TF expression and VEGF 
concentrations, where high concentrations of VEGF in cancer patients correlates with 
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increased expression of TF by endothelial cells in the tumor vasculature (Bambace and 
Holmes, 2011). This expression may explain the increased incidence of thrombosis in 
cancer patients. Furthermore, Thrombin concentrations have been reported to increase 
dramatically in cancer patients compared to healthy subjects and this also promotes 
activation of platelets and release of their angiogenic proteins (Bambace and Holmes, 
2011). 
 
If platelets contain both pro-angiogenic and anti-angiogenic factors, stimulating release 
of both of these equally should neither promote nor inhibit angiogenesis. However 
evidence suggests that there is selective release of such factors; Activation of platelets 
via ADP-P2Y12 receptor interactions results in the release of VEGF but not endostatin, 
leading to an overall pro-angiogenic effect in this setting (Sabrkhany et al., 2011). A 
review by Almog et al. (2010) highlights the importance of balancing pro- and anti-
angiogenic factor release by platelets on tumour progression (Fig. 1.4). In a healthy 
mouse, these factors are in fine balance, while in mice with dormant or inactive cancers 
there is an imbalance, in favour of the anti-angiogenesis proteins. In contrast, mice with 
active tumours express higher levels of the pro-angiogenic factors (Almog and Klement, 
2010). 
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In addition to releasing factors that may promote cancer growth, platelets can also 
uptake or sequester some tumor-derived proteins that appear essential for tumor 
metastasis (Bambace and Holmes, 2011). A study by Klement (2004) revealed that the 
concentrations of angiogenic proteins inside platelets from animals bearing malignant 
cancer were significantly higher than in platelets from healthy animals. Furthermore, 
when VEGF was injected into these mice subcutaneously, the level of VEGF in platelets 
increased without significantly changing the overall plasma concentration, providing 
evidence that platelets selectively uptake certain proteins from their microenvironment 
(G. L. Klement et al., 2009). This is selective as other proteins such as albumin, that are 
also at high concentration in the plasma are not taken up by platelets (G. L. Klement et 
al., 2009). 
 
Figure 1.4  Importance of balancing pro- and anti-angiogenic factors. In the healthy mouse model (left), 
there is balance between Anti-angiogenic (Yellow circle symbol) and Pro-angiogenic (blue plus symbol) 
factors, while in the mouse with dormant or inactive cancer (centre), there is an imbalanced level of 
these proteins which is in favour of anti-angiogenic proteins. In the active cancer model (right), the 
mouse expresses the highest level of pro-angiogenic factors (Taken from Almong & Klemnt, 2010). 
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Platelets isolated from glioma and prostate cancer patients have been found to contain 
tumor associated RNA, EGFRVII and PCA3. It is proposed that these could be considered 
as biomarkers and analysis of platelet contents in such patients could be a useful, non-
invasive test for the diseases (Nilsson et al., 2011). Specific gene expression signature in 
platelets from cancer patients also suggests that analysis of platelets may be useful in 
the diagnosis of cancer and the monitoring of disease progression (Nilsson et al., 2011). 
Literature evidencing the uptake of tumour-derived proteins is summarized in Table 1.5.  
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Table 1-5 Summary of literature evidencing the uptake of tumour-derived proteins by platelets in 
different cancer types 
 Author  Cancer type Sequestered tumour-derived factors by platelets 
Klement et al., 2009  Malignant animal – breast cancer VEGF  
Nilsson et al., 2011  Glioma and prostate cancer  Tumour associated RNA (EGFRVII and PCA3) 
(Kerr et al., 2010)  Human prostate cancer cell TGF-β1, VEGF, MCP-1, MMP-2, RANK, RANKL and TIMP-1. 
(Fu et al., 2015) Non-small cell lung cancer (NSCLC) VEGF 
(Benoy et al., 2002)  Breast cancer VEGF 
(G. Klement et al., 2004)  Human tumour injected in mice  VEGF, bFGF, PDGF, BDNF, endostatin 
(Peterson et al., 2012) Colorectal cancer  VEGF, PDGF and PF4 
(Cervi et al., 2008)  Liposarcoma  PF4  
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The uptake of tumour-derived proteins and cytokines by platelets is thought to protect 
these molecules from degradation in the general circulation (Kerr et al., 2010). Tumor-
derived VEGF and TGF-β1 which aid tumor progression and metastasis, are preferentially 
taken up and stored in platelets, where their levels are 1.4 and 1.96 fold higher 
respectively than in plasma (Kerr et al., 2010). As a result of this sequestration of tumor 
proteins, it is suggested that platelets can play important roles in metastatic processes 
by transporting these factors to distant sites within the body (Kerr et al., 2010). 
Furthermore, platelets also have a protective effect on tumor cells, binding to them via 
platelet activating factor and shielding them from immune detection by Natural Killer 
(NK) cells. This also enhances extravasation and metastasis (Bambace and Holmes, 
2011). The uptake of relatively high concentrations of tumour-derived factors could 
affect the haemostatic function of platelets, but to date, solid conclusions have not been 
made.  
 
1.8.2.1 Evidence of Haemostatic abnormalities in cancer patients. 
Armand Trousseau first described the link between cancer and haemostatic 
abnormalities in 1865. Thereafter, unexpected and unexplained thrombotic problems in 
carcinoma patients was termed Trousseau syndrome (Varki, 2007). The underlying 
mechanisms are still not understood and may be multifaceted. Tissue Factor (TF) 
expression and up-regulation of the thrombin receptor (PAR-1) by some cancer cells are 
two proposed explanations for this link. TF and Thrombin receptor expression cause 
thrombosis either locally at the site of the tumor, or at distant sites in the body (Varki, 
2007). However, some patients with low expression of TF and thrombin receptor may 
still present with thrombotic complications, suggesting alternative underlying 
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mechanisms (Falanga et al., 2013). A large number of studies report on the percentage 
of thrombosis or active bleeding in cancer patients (Table 6.2). Surprisingly, incidence of 
venous thromboembolism (VTE) in cancer patients is reported to be seven fold higher 
than in a healthy population (Falanga et al., 2013). On the other hand, active bleeding is 
also seen in cancer patients and is an important cause of death in 10% of solid tumor 
patients, a figure which is suggested to be even higher in patients with haematological 
malignancies (Falanga et al., 2013).  
 
Klastersky et al. (1971) reported severe haemorrhage in patients with acute leukemia 
where 30% of patients died as a result. Although thrombocytopenia is often a symptom 
of this disease, it was proposed that this decrease in platelet count was not the only 
factor involved in the fatal bleeding, suggesting that thrombocytopathy in the presence 
of adequate platelet counts may also be important (Klasters.J et al., 1972). 
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1.8.2.2 The link between tumour-derived proteins and platelet function 
Tumour-derived proteins may interfere with platelet function and may lead to 
thrombosis (hyperactivity) or risk of bleeding (hypoactivity). A large body of evidence 
exists documenting changes in serum concentrations of cytokines and growth factors in 
cancer patients, compared to control patients (examples in table 1.6), and so it is not 
unreasonable to propose that this may be the cause of the observed haemostatic 
disturbances. Interestingly, the collective data highlight several cytokines that are at 
higher concentrations in the serum of patients with different types of cancer, notably 
IL-6, TNF-a and VEGF. Furthermore, it is suggested that tumor-derived IL-6 has a role in 
the regulation of VEGF inside the platelets of breast cancer patients, illustrating the link 
between IL-6 in serum and VEGF in platelets (Benoy et al., 2002).   
 
Furthermore, Rubenstein et al. (2002) have shown that overexpression of VEGF in an 
animal model with glioblastoma induces vascular destabilization which lead to 
intracerebral haemorrhage and spontaneous tumor haemorrhage (Rubenstein et al., 
2002). Moreover, Peterson et al. (2012) revealed that platelets from colorectal cancer 
patients have significant increases in VEGF. PDGF, PF4 (Peterson et al., 2012). 
Author Cancer type Cytokines in peripheral 
blood  
(Kerr et al., 2010)  Human prostate cancer cell G-CSF, HGF, IL-1β, 
MMP-9 and OPG. 
(Fu et al., 2015) Non-small cell lung cancer (NSCLC) TGF-β1 
(Benoy et al., 2002)  Breast cancer VEGF, IL-6 
Table 1-6 Examples of elevated cytokines in peripheral blood of some cancer patients. 
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1.8.3 The role of platelets in cancer  
Platelets play vital role in haemostasis and thrombosis and recently they have also been 
involved in inflammatory and angiogenesis process (Morrell et al., 2014; Sabrkhany et 
al., 2011; Ronnlund et al., 2012; Almog and Klement, 2010). Moreover, it has been found 
that platelets consider as key mediator of tumour metastasis (Almog and Klement, 2010; 
(Sabrkhany et al., 2011) . Surprisingly, patients with cancer wether solid tumour or 
haematological malignancy have abnormal haemostatics parameters, which may lead 
to thrombosis or active bleeding (Ronnlund et al., 2012). This indicates that cancer cell 
or neo-angiogenesis process may affect on platelets function in these patients. 
  
There are large body of evidence demonstrate that platelets sequester many 
microenviromental factors which could be the reason for abnormal function of platelets 
in the case of cancer patients where cancer cell secrete abnormal level of proteins in the 
circulation (Peterson et al., 2012; Nilsson et al., 2011; G. L. Klement et al., 2009; G. 
Klement et al., 2004).  Some of these factors that are sequestered in platelets have been 
found to be cancer specific which may give advantage to platelet to be test as early 
tumour detection in cancer patients.  
Moreover, other studies have reported the percentage of thrombosis and bleeding in 
cancer patient are increase (Table 6.1). Surprisingly, it has been reported that VET 
incidence in cancer patients seven times higher than healthy people (Falanga et al., 
2013). On the other side, active bleeding has also been seen in cancer patients which 
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consider as an important cause of death in 10% of solid tumour patients. As results of 
that haematological malignancy could be higher even than the solid tumour. 
 
1.9 Role of endothelial cells in haemostasis  
Clot formation results from the interplay between platelets, coagulation factors and also 
endothelial cells on the vascular wall (Wu and Thiagarajan, 1996; Verhamme and 
Hoylaerts, 2006). The main function of the endothelial cells in haemostasis is to maintain 
blood fluidity and limit thrombus plug formation to a very localised area. Endothelial 
cells release anti-platelet and anti-coagulant factors to supress platelet activation and 
fibrin formation. Therefore, endothelial dysfunction not only precedes atherogenesis 
but may also predispose to arterial thrombosis.  
 
Under normal conditions, endothelial cells release Nitric Oxide (NO), prostacycline 
(PGI2) (Verhamme and Hoylaerts, 2006) and prostagladine E2 (PGE2). These molecules 
work to inhibit platelet activation (and reverse platelet aggregation) by increasing cyclic 
AMP (Cattaneo and Lecchi, 2007). Additionally, endothelial cells present/release a 
whole host of other factors which act to inhibit platelets, fibrin formation and 
coagulation factor activation. There are summarised in table 1.7. 
 
During endothelial injury or dysfunction, expression/secretion of these anti-thrombotic 
properties is reduced/lost, and the cells express pro-thrombotic molecules such as VWF 
and collagen from the sub-endothelial matrix.  This leads to adherence of platelets to 
VWF and collagen where they become active and release secondary mediators such as 
ADP and TXA2 (Wu and Thiagarajan, 1996) thereby amplifying the platelet response. 
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Therefore, inherent platelet hyperactivity is not the only cause of inappropriate platelet 
aggregation and endothelial dysfunction can lead to the same effect. The role of the 
endothelium must be considered when investigating disorders of inappropriate 
thrombus formation. 
 
 
 
 
Table 1-7 Summary of Endothelial molecules function in haemostasis adapted from (Wu and 
Thiagarajan, 1996). 
 Endothelial mediators Function  
Anticoagulant molecules  Prevent thrombosis 
PGI2 Inhibit platelet function 
NO Inhibit platelet function 
tPA Enhance fibrinolysis system 
TFPI Inhibit coagulation factor Xa and VIIa/TF complex. 
Thrombomoduline Modify thrombin substrate to induce protein C activation 
Protein S Enhance protein C to inactivate factor Va and VIIIa. 
Heparan Sulfate 
proteoglycan  
Cofactor for antithrombin III 
Ecto-ADPase Inactivate ADP and suppress platelet aggregation 
Procoagulant molecules  Form thrombosis at injured tissue to stop bleeding or may 
cause thrombotic complication at abnormal plaque formation 
VWF Induce platelet adhesion and activate factor VIII. 
PAI-1 Inhibit tPA 
TF Cofactor for factor VIIa 
Factor Va Induce activation of factor Xa 
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1.10 Platelet function tests 
Platelet function tests are very important in the investigation of haemostatic disorders 
and the effects of antithrombotic therapy. Recently, it has become common to use 
platelet function testing for monitoring antiplatelet therapies in cardiovascular disease 
patients, allowing determination of the optimal dose of antiplatelet therapy (Michelson 
et al., 2006). 
 
1.10.1 Light transmission aggregometry (LTA) 
LTA is  the “gold standard” test for platelet function. The platelet aggregometer consists 
of a cuvette for the sample and source of light and a detector. The principle depends on 
turbidity of a sample of platelet-rich plasma (PRP) in the cuvette. When the platelets are 
in single form and not-aggregated, the sample of light passing through the cuvette is 
absorbed by the sample. Once an agonist is added, the platelet begins to aggregate the 
sample becomes translucent and more light passes through the sample. This is seen as 
a change in absorbance. A sample of platelet-poor plasma (PPP) is used as a comparator 
for 100% aggregation (Born, 1962; O'brien, 1962; Natalia Dovlatova et al., 2015; 
McFadyen et al., 2018). The change in absorbance is measured over 5 minutes, and so 
the method can very quickly give an indication of platelet function in a patient. 
 
 
1.10.2 Impedance aggregometry  
Impedance aggreometry (or Whole Blood Aggregometry, WBA) is based on the principle 
of electrical impedance by platelets aggregating and binding to an electrode. Two 
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electrodes are inserted into an anticoagulated whole blood sample and an alternative 
current is pass between them (May et al., 2004). When platelets are activated by an 
agonist, they accumulate around the electrode and increase the impedance, which is 
measure in Ohm (Ω). This increase in impedance is directly proportion to the degree of 
platelet aggregation (May et al., 2004).   
 
One of the advantages of this method is it does not need any sample preparation as it 
uses whole blood. Further, the conditions are said to be more reflective of the in-vivo 
environment, and so any effect of an anti-platelet agent by impedence aggregometry 
can be assumed to be the same in-vivo.  However, in contrast, using a whole blood 
sample may produce in-vitro artefacts which interfere with the result and hence there 
is an argument that LTA is the superior method (von Beckerath, 2008). 
1.10.3 Platelet function analyzer-100 (PFA-100) 
PFA attempts to mimic the in-vivo platelet function at the site of injury. The machine 
consists of a disposal cartridge that has a reservoir for the sample, capillary of coated 
membrane with collagen/ADP or epinephrine with 150μm aperture. The principle of the 
machine is based on time occlusion of the aperture by a platelet plug formation (May et 
al., 2004). This is rapid and simple to perform with less technical skill than LTA or WBA 
(May et al., 2004).However, this test needs quality control to give optimal results 
compared with other laboratory and is relatively expensive in comparison with LTA and 
WBA.  
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1.10.4  Flow cytometery for platelet activation 
Flow cytometry allows for the analysis of platelet surface activation markers. Two of the 
most commonly analysed markers are CD62P (P-Selectin) which is released from α-
granules following platelet activation, and activated αIIbβ3 which allows for fibrinogen 
binding. The method provides rapid analysis in PRP and also whole blood samples. In the 
case of whole blood sample, platelets are often identified in the sample by staining with 
a platelet-specific CD41, in combination with antibodies targeting the activation 
markers. The blood sample is pre-incubated with a fluorochrome-conjugated antibody 
which binds to the target antigen on the platelet surface. If bound, the fluorophore will 
excite at the specified wavelength and is detected by photomultiplier detector and 
converted into electronic signal that proportion to the number of antibodies (Ab) on 
platelet surface (May et al., 2004). This method can be used to predict the risk of 
recurrent thrombotic event in ACS patients who are under anti-platelet drug such as 
clopidogrel (Dovlatova et al., 2015). 
 
Flow cytometry can also be used to assess the formation of platelet-leukocyte 
aggregates, which rapidly form following platelet activation. Expression of CD62P on 
platelet surface leads to initiate the link with its precursor P-selectin glycoprotein-1 
(PSG-1) on leukocytes. This leads to platelet leukocyte interaction, which indicate a 
better result of platelet activation through P-selectin. Duel labelling with a leukocyte 
marker (CD45) and platelet marker (CD42b) can be used to identify double-positive 
events within the sample, and thus platelet-leukocyte aggregates (Gibbins et al., 2004). 
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1.10.5 Ca2+ flux assay 
Intracellular Ca2+ is a key indicator of platelet activation. Binding of a platelet agonist 
with its receptor leads to PLC signalling, IP3 generation and subsequent release of Ca2+ 
from the granules into the cytosol, and also entry of extracellular Ca2+ via ion channels 
in plasma membrane. Elevation in the level of intracellular Ca2+ plays an important role 
in platelet shape change, aggregation and degranulation (Gibbins et al., 2004; Assinger 
et al., 2015). 
 
Ca2+ flux in platelets (and other cells types) is a rapid process occurring within 
microseconds after addition of the agonist. This poses a challenge for most assays used 
to investigate changes in intracellular Ca2+. Most studies utilise confocal microscopy, 
plate-based assays, spectrofluorometry, and standard flow cytometry for such 
measurements, although there are issues with the number of cells that can be analysed 
or gaps in recording due to the addition of stimulants, with significant loss of detail of a 
rapid Ca(2+) response (Vines et al., 2010). Continuous flow cytometry, on new 
generation flow cytometers allows for constant analysis of a sample before, during and 
after addition of a stimulant. This has revolutionalised the study of Ca2+ signalling as 
spikes in intracellular Ca2+ are seen in real-time. There are several indicator dyes that 
can be used to bind to cytosolic Ca2+ including Fura-2, Indo-1, Fluo-3 and Fluo-4. These 
dyes passively cross the plasma membrane and bind to cytosolic Ca2+, reporting any 
spike in intracellular concentration has an increase in fluorescence (Morgan, 1993; 
Gibbins et al., 2004; Assinger et al., 2015). 
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1.11 Thesis Aims: 
Platelets have both haemostatic and inflammatory roles and platelet dysfunction leads 
to a wide variety of conditions. For haemostatic disorders such as ACS, which may result 
in MI or stroke, modulation of platelet activity is vital. However, current anti-platelet 
therapies have their limitations; those used extensively such as aspirin and clopidogrel 
do not show effectiveness in all patients, and hyperactivity can continue in patients 
taking these drugs. In contrast newer agents such as ticagrelor show superiority in terms 
of platelet inhibition but are associated with increased bleeding tendency. There is 
therefore a need for continued development and refinement of anti-platelet therapies.  
 
This study aimed to investigate the use of novel thienopyridine derivatives as anti-
platelet agents. The study achieved this aim via completion of the following objectives: 
 
Objectives: 
1. Analysis of the effect of six novel thienopyridine derivatives on the platelet 
activation and function, and comparison of these effects with those observed 
following use of conventional anti-platelet therapies 
2. Analysis of the effect of the novel thienopyridine derivatives on the platelet 
signalling pathways, and comparison of these effects with those observed 
following use of conventional anti-platelet therapies. 
3. Analysis of the effect of these novel thienopyridine derivatives on endothelial 
function, in terms of their ability to supress agonist-induced adhesion molecule 
expression 
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4. The ability of microenvironmental factors (using a co-culture model) to affect 
platelet function, with the aim of providing a basis for future investigation of the 
effects of anti-platelet therapies on the immunological function of platelets. 
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2 Chapter 2: Materials and Methods 
 
2.1  Thienopyridine derivative synthesis 
Thienopyridines were synthesised by our collaborators at the School of Chemical 
Sciences, University of Auckland, New Zeland, and as previously described (Leung et al., 
2014; Hung et al., 2014; Arabshahi et al., 2015; Leung et al., 2016). Briefly, the 
appropriately 5,6-disubstituted-2-thioxo-1,2-dihydropyridine-3-carbonitriles were 
condensed with substituted 2-bromo-N-phenylacetamides to give the desired 
thieno[2,3-b]pyridines. All compounds were obtained as pure solids after 
recrystallisation from an alcoholic solvent and their structures were confirmed using 
NMR and mass spectrometry.  
The molecular structures of the six derivatives are demonstrated (Table 2.1).  
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Name Molecular Weight Chemical Structure 
Clopidogrel 
active 
metabolite 
355.5 
 
DJ0206 444.39  
DJ0081 385.91  
DJ0021 381.49 
 
DJ0171 371.84 
 
DJ0097 371.84  
DJ0199 351.47  
 
2.2 Ethics 
The Manchester Metropolitan University ethics board granted approval for the study. 
Healthy volunteers were recruited for blood collection and gave written informed 
consent before donating a blood sample. Participants who had taken anti-platelet 
medication, anti-inflammatory medications, herbal medicines that may interfere with 
platelet function (Ginko Biolba, St John’s Wort) or Selective Serotonin Reuptake 
Inhibitors in the past fortnight were excluded from the study. The study involved a total 
Table 2-1 Chemical structure of thienopyridine derivatives used in this study 
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of sixty-two participants (n=40 male, n=22 female, age range 20-38). Samples from some 
participants (chosen at random) were used for analysis of multiple markers of platelet 
activation and function. 
 
2.3 Sample Collection and Platelet-rich Plasma (PRP) purification 
Blood samples were collected from the median cubital vein of healthy volunteers by 
using sodium citrate vacutainer tubes. The vacutainers were centrifuged at 180 g for 15 
minutes at 20 °C. Then Platelet Rich Plasma (PRP) was aspirated carefully from the top 
layer and transferred to a fresh tube.  The centrifugation was stopped with zero break 
to avoid remixing the PRP with the red blood cell layer. 
PRP was then diluted at a 1:1 ratio with Tyrode’s buffer (NaCl (134 mM), KCl (2.9 mM), 
Na2HPO4 (0.34 mM), NaHCO3 (12 mM), MgCl2 (1 mM), HEPES (20 mM), Glucose (5 mM), 
adjusted to pH 7.4). Platelet Poor Plasma (PPP) was also prepared for the Light 
Transmission Aggregometry (LTA) experiment – A 500 µl volume of diluted PRP was 
centrifuged at 5000 g for 5 minutes at 20°C to aspirate PPP from the platelet pellet.  
 
2.4  Washed platelet preparation  
Blood was collected in Acid Citrate Dextrose (ACD) vacutainer tubes. PRP was prepared 
as in section 2.3, and apyrase 0.2u/ml (Sigma-Aldrich, UK) was added to the PRP. The 
sample was centrifuged again at 2200g for 10 min at 20°C to obtain the platelet pellet 
and the supernatant was discarded. The pellet was resuspended in Tyrode’s buffer 
containing 0.35% Bovine Serum Albumin (BSA) (Sigma-Aldrich, UK). The platelet count 
was then adjusted to 8*108/ml in Tyrode’s buffer.  
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2.5  Drug treatments 
Unless otherwise specified, for experiments involving PRP, a 400µl volume of diluted 
PRP was treated with 50µl thienopyridine (final concentration 10µM) for 30mins at 37°C. 
In experiments involving whole blood, 500µl whole blood was treated with 500µl 
thienopyridine (final concentration 10 µM) or vehicle control for 30mins. In ASA synergy 
experiments, 400µl samples of diluted PRP were treated with 25µl thienopyridine and 
25µl ASA (final concentration 30M). Following treatment diluted PRP or whole blood 
samples were analysed using light transmission aggregometry or impedance 
aggregometry respectively. 
 
2.6 Platelet Activation Studies by Flow cytometry 
Flow cytometry was used to assess platelet activity by labelling platelets with 
fluorochrome-conjugated anti-CD62P (BD Bioscience, UK, Cat: 555524) and PAC1 (BD 
Bioscience, UK, Cat: 091515). CD62P expression gives an indication of alpha granule 
release, while PAC-1 binding reflects expression on the activated fibrinogen receptor 
(GP IIb/IIIa). A 90µl volume of control or treated PRP was stimulated with 10l of 10M 
ADP (Sigma-Aldrich, UK) before addition of 10l PE-conjugated CD62P (BD Biosciences, 
UK) and 10l FITC-conjugated PAC1 (BD Biosciences, UK) and incubation for 10 minutes 
at 20oC. A 100l volume of 4% paraformaldehyde (PFA) (Sigma, UK) was then added to 
arrest any further reaction, holding the platelets in an activated state. A 300µl volume 
of DPBS (Lonza, UK) was added and samples were analysed on the FACS Verse flow 
cytometer (Becton Dickinson). Each sample was run in duplicate. Platelets were gated 
using FSC/SSC for size/granularity, and FITC and PE Mean Fluorescence Intensity (MFI) 
were recorded. 
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Platelet leukocyte aggregates (PLAs) were used to further assess platelet activation. A 
5µl volume of control or thienopyridine-treated whole blood was diluted with 55µl DPBS 
and then stimulated with a 10µl volume of 10µM ADP.  A 10l volume of each of PE-
conjugated CD45 (BD Biosciences, UK) and FITC-conjugated CD42b (BD Biosciences, UK) 
were added to the mixture and incubated for 20 minutes at 20oC. Samples were then 
diluted with 1ml DPBS and analysed immediately on the FACS Verse flow cytometer. 
Each sample was run in duplicate. 
 
2.7 Light transmission aggregometry (LTA) 
The drug-treated PRP samples (450 µL volume) were placed in glass cuvettes with a stir 
bar and placed in the Chronolog 700 aggregometer (Chronolog, USA) at 37oC. After 1 
minute of baseline reading, 50l of ADP (final concentration 10 µM) (Labmedics, UK) or 
collagen (final concentration 1 µg/ml) (Chronolog-Corp, USA) was added and the 
aggregation (MaxA) was recorded for a further 4 minutes. A 500l volume of PPP was 
placed in the analyser for calibration to 100% light transmission. Each sample was run in 
triplicate. 
 
2.8 Ca2+ Assay  
For the Ca2+ assay, washed platelets were prepared. Citrated whole blood was 
centrifuged at 200g for 20 mins. The PRP was carefully aspirated from the red cell layer 
and transferred into a fresh tube. A 2U/ml concentration of apyrase was added to the 
sample. The sample was further centrifuged at 1800 g for 10 minutes and the plasma 
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was removed from the platelet pellet. The pellet was resuspended in 5ml Tyrodes-Hepes 
buffer (NaCl 134 mM, KCl 2.9 mM, Na2HPO4 0.34 mM, NaHCO3 12 mM, MgCl2 1 mM, 
HEPES 20 mM, Glucose 5 mM, pH 7.4). A 1 µl volume of 4µM Fluo4-AM (Invitrogen, UK) 
and 0.2% pluronic was added to 1000 µl of the sample which was incubated for 45 min 
@37°C in the dark. The sample was centrifuged at 1800xg, 10min to remove excess dye. 
The platelets were then diluted in Tyrode’s buffer to the desired density (2-4 x 
108cells/ml). Finally 0.162u/ml apyrase was added again to reduce de-sensitization of 
the ADP receptors prior to analysis. 
The Fluo4-AM loaded washed platelet samples were then treated with thienopyridine 
for 30 mins and were then analysed on a Accuri C6 Flow Cytometer, where ADP was 
used as the agonist during sample acquisition. 
 
2.9  Cell culture 
The HUVEC cell line (ATCC, Middlesex, UK) was used in this study to test the effect of 
thienopyridine compounds on endothelial cells. As these cells are adherent cells they 
were cultured in 1% Gelatin coated flasks (Thermo Scientific, UK) using M199 culture 
medium (Lonza, UK) containing 10% Fetal Bovine serum (FBS) (Gibco, Switzerland) and 
maintained at 370C in a humidified environment of 5% CO2 in air. The passagings of these 
cells were performed by routine trypsinisation (Lonza, UK) and replacement of fresh 
M199 medium. Cell viability was assessed using the Trypan blue exclusion method on a 
haemocytometer, and experiments were only performed when cell viability was >95%. 
 
The Hodgkin lymphoma cell line L1236 (ATCC, Middlesex, UK) was used in this study. 
Cells were routinely passaged and maintained in RPMI media (Lonza, UK), supplemented 
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with 15% FBS at 370C in a humidified environment of 5% CO2 in air. Cell viability was 
assessed using the Trypan blue exclusion method on a haemocytometer, and 
experiments were only performed when cell viability was >95%.  
 
2.10  Epi-Fluorescence Microscopy  
Human Umbilical vein endothelial cells (HUVEC) cells were cultured for 24 hours on glass 
cover slips and fixed with 4% formaldehyde in phosphate buffered saline (PBS) for 10 
minutes at room temperature. Then HUVEC were permeabilised with 1% triton-100 in 
PBS for 5 minutes and blocked with blocking buffer (5% goat serum and 0.1% triton x-
100 in PBS) for 1 hour at room temperature. Then the cells were labelled with mouse 
anti-CD62P (Abcam, UK, Cat: NB100-65392) and rabbit ant-CD62E (Abcam, UK, Cat: 
ab18981) in primary solution (1:1 ratio of blocked buffer and PBS) with 1:300 ratio. 
Following incubation overnight in the dark at 4°C, the HUVECs were stained with 
secondary antibody Alexa-568 anti-rabbit IgG (Invitrogen, UK, Cat: A11011) and Alexa-
647 anti-mouse IgG (Invitrogen, UK, Cat: A21235) simultaneously, in primary solution at 
1:500 ratio. The cells were stained with one drop of DAPI (diamidino-2-phenylindole) 
mounting solution (Vector Shield Laboratories, UK, Cat: H1200) overnight at 4°C and 
covered from light ready for EPI microscopy. For Epi-fluorescent microscopy the Zeiss 
imager Z1 microscope was used and 40x lens was obtained the images from.  
 
2.11 Western Blotting 
Washed platelet samples were treated with thienopyridines as described in section 2.0. 
Following a 30 minute incubation, the samples were stimulated with 10µM ADP and 
immediately centrifuged for 5 min at 1500 g. The supernatants were discarded and the 
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platelet pellets were resuspended in 200 µl Pierce ™ radioimmunoprecipitation assay 
(RIPA) buffer (Thermo Scientific), containing a 1:1000 dilution of both phosphatase and 
protease inhibitors to protect platelet proteins from denaturation. The samples were 
vortexed and placed on ice for 30 minutes. Vortexing was performed every 5 minutes 
until the end of the 30 minutes duration. Subsequently, mixtures were put in an 
ultrasonic bath- Grant- XUBA3 (sonicator) for 3 minutes to ensure the breakdown of 
platelet membranes. Samples were then centrifuged at 13500 g for 20 minutes and the 
supernatants (platelet lysates) were then frozen at -20°C until further analysis. 
 
2.11.1 Protein Assay 
Protein assays were performed using the BCA Protein Assay (Thermo Scientific) to 
quantify the proteins in the platelet lysates prior to Western blotting to normalize lane 
loading. The BCA assay is a colorimetric technique, which depends on cupric ions (Cu2+) 
reduction by peptide bonds in proteins. The amount of reduced Cu2+ ions is directly 
proportional to the amount of proteins existing in the sample. When the BCA reagent 
binds to Cu2+ ions, a purple-coloured substance is formed and absorbs the light at a 
wavelength of 562 nm. 
 
Bovine Serum Albumin (BSA) protein standards were prepared by diluting the BSA 
standard samples (2 mg/mL) (Thermo Scientific, 23209) in RIPA buffer at concentrations 
of 2, 1.6, 1.2, 0.8, 0.4 ,0.2 and 0  mg/ml. Platelet lysates were diluted twice with RIPA 
buffer at ratios of 1:1 and 1:2 in order to ensure that final absorbance values following 
BCA assay were within the range of the standard curve.  
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BCA reagents A & B were mixed in a ratio of 1:50. A 200μL volume of the mixed solution 
was added to a 96 well plate with 10μL of the protein samples or standards. The 96 well 
plates were incubated at 37oC and absorbance was recorded after 30 minutes at 562 nM 
using a Bio-Tek ELISA plate reader (Winooski, VT, USA). The sample protein 
concentrations were calculated from the standard curve that was generated 
automatically by plotting the average of loaded BSA standard at 562 nm against the 
known concentration in mg/ml.  
 
2.11.2  Gel Electrophoresis 
Following protein extraction and determination of protein concentration, samples were 
loaded according to protein concentration (12μg per sample in a maximum 30μL total 
volume used). An 8μL volume of Precision Plus proteins Dual standards markers (Bio-
Rad, UK), was prepared alongside the samples, as a reference for the molecular weight 
of migrating proteins. Loading buffer was made up by diluting nine part of 4x Laemmli 
Sample Buffer (Bio-Rad, UK) in  one parts of 2-mercapto-ethanol. Each platelet lysate 
sample was then diluted in loading buffer at a ratio of 1:3. Samples were boiled at 100◦C 
for 10 minutes, in order to reduce disulphide bonds and facilitate protein denaturation, 
followed by immediate transfer to ice. 
 
The resolving gel was prepared by using TGX and TGX Stain-Free Fast Cast kit ( Bio-Rad, 
USA) where a 1:1 ratio of resolver A and B were mixed together to make the resolver 
solution (3ml each to do 1mm glass plate). This was followed by addition of 30 μL of 10% 
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ammonium persulfate (APS) and 3 μL of  N,N,N,N'-tetramethylenediamine (TEMED) per 
cassette, which form a polymer network/mesh that catalyzes the polymerization of the 
reaction. The stacking gel was prepared by mixing a stacker A and B in a 1:1 ratio 
followed by addition of 2 μL TEMED and 10 μL APS per cassette. The resolving gel and 
stacking gel were assembled in a Bio-rad glass cassette and a comb was inserted over 
stacking gel solution. The gel was left for 1-2 hours to allow time for solidification. 
 
Following gel formation, the glass plate holding the gel was placed in the electrophoresis 
chamber. Running buffer was prepared (25 mM Tris, pH 8.3, 190 mM glycine, 0.1% SDS 
in dH20) and used to completely cover the gel. The leakage of running buffer through 
the stands holding the gel was prevented. The chamber was then filled with the running 
buffer until the level reached the first green bar in the stand holding the glass plates. 
The comb was removed gently from the gel and 20 µL of Precision Plus Protein TM Dual 
Colour standards was loaded into the first well of the gel, then 20 µL of each sample was 
loaded in the following wells. The gel was run at 400 MA, 100 V for 10 minutes until the 
bromophenol blue dye, included in the sample buffer, reached the interface between 
the stacking and the resolving gels. Voltage was subsequently increased to 200V for 
approximately 30 minutes until the bromophenol blue dye reached the end of the 
resolving gel. 
 
2.11.3 Blotting  
Once the protein has been separated by gel electrophoresis, proteins were transferred 
to a nitrocellulose membrane (TransBlot Turbo mini-size nitrocellulose) (Bio-Rad, USA). 
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The blotting was performed by semi-dry method using the Trans-Blot Turbo Blotter 
(BioRad, USA). Two filter papers were immersed in transfer buffer before using to create 
a  sandwich with the gel and the nitrocellulose membrane between them. The sandwich 
was placed into the TransBlot system and run at 25 Volts for 7 minutes for transfer to 
take place.  
 
2.11.4 Blocking 
A blocking stage was needed to prevent any non-specific binding between the primary 
antibody and non-target proteins on the blot. Bovine serum albumin (BSA) (Sigma-
Aldrich, UK) 2% in TBST was used to block the membrane for 1 hour at R.T. on a shaker.   
 
 
 
 
2.11.5 Detection 
For detection of target proteins, primary antibodies (Ab) (Table 2.2) were diluted in 
blocking buffer (1:1000) and incubated with the membrane overnight at 4°C on a 
shaking machine. The following day, the primary Ab solution was discarded and the 
membrane was washed 3 times with Tris-buffered saline with tween 20 (TBST) for 5 
minutes per wash on shaker at R.T.  The membrane was then incubated with a secondary 
Ab, anti-rabbit IgG-Horseradish Peroxidase (HRP) (Table 2.2) for 1 hour at R.T on a 
shaker. The membrane was then washed 3 times again as before prior to exposure to 
enhanced chemilluminescence (ECL). The substrate used for this is Piece ECL Western 
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Blotting substrate (Thermo Fisher, UK). It was prepared by mixing reagent A with reagent 
B in 1:1 ratio and 1 ml of the mixer was added to cover the membrane for 5 minutes at 
R.T without shaking. Finally, the membrane was analysed using the BioRad imaging 
system where the chemiluminescence produced from enzymatic reaction between HRP 
on the secondary Ab and the ECL substrate, is proportional to the amount of protein in 
the membrane (Dimechev, 2012). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Detection and quantification of target proteins. Target proteins, transferred 
to nitrocellulose membranes, are bound by primary antibodies, which are recognized 
by enzyme-conjugated secondary antibodies. The enzyme, such as HRP, participates 
in a chemical reaction when a specific substrate is added, resulting in the emission of 
a detectable signal. The light signal can be detected by a camera, enabling the semi-
quantification of the target proteins present on the nitrocellulose membrane (adapted 
from Leinco Technology, 2018) 
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VASP: Vasodilator-Stimulated phosphoprotein, Akt also known protein kinase B, PLCγ2 : phospholipase C 
gamma 2, cPLA2: cytosolic phospholipase A2.  
 
 
 
 
Table 2-2 Antibodies lists that used for western blot. 
Antibody Company supplier Catalogue Number Dilution 
VASP Cell Signalling 
Technology, UK 
3132 1:1000 
p-VASP Cell Signalling 
Technology, UK 
3114S 1:1000 
Akt Cell Signalling 
Technology, UK 
9272S 1:1000 
p-Akt Cell Signalling 
Technology, UK 
9271S 1:1000 
PLCγ2 Cell Signalling 
Technology, UK 
3872 1:1000 
p-PLCγ2 Cell Signalling 
Technology, UK 
3874S 1:1000 
cPLA2§ Cell Signalling 
Technology, UK 
2832S 1:1000 
p-cPLA2 Cell Signalling 
Technology, UK 
2831 1:1000 
Anti-Rabbit Igg-HRP 
Linked Ab 
Cell Signalling 
Technology, UK 
7074S 1:1000 
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2.11.6 Nitrocellulose Membrane Stripping and Re-Probing 
Nitrocellulose membrane stripping was performed to enable re- probing of the 
membrane using alternative primary antibodies. To strip, membranes were incubated 
15 minutes at RT with Restore Western Blot Stripping Buffer (Thermo, Rockford, USA). 
Nitrocellulose membranes were washed three times, for 5 minutes each time with TBST 
and then re-blocked by incubating with blocking buffer for 1h at RT on a shaker. When 
blocking buffer has been removed, the membrane was incubated with anti-β-actin (New 
England Biolabs) or an antibody to the unphosphorylated form of the protein under 
investigation (Anti-total VASP, Anti-total Akt, Anti-total PLCγ2, anti-total cPLA-2) (New 
England Biolabs)) at 4°C on the shaker, overnight. The primary and the secondary 
antibodies were prepared by diluting with 2% BSA (1 in 1000 dilution). Thereafter, the 
membrane was washed with TBST three times and incubated with the secondary 
antibody and then with the chemiluminescent substrate as described previously, and 
blots were visualised using the imaging system. 
  
Densitometry was applied for quantifying the proteins after each visualization step. 
Where appropriate, all phopshorylated forms of proteins investigated were normalized 
either to their respective total protein levels or to β-actin. All antibodies used for 
western blotting analysis were purchased from New England Biolabs (Hertfordshire, 
UK). 
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2.12 Statistical analyses 
All data normalisation was performed using Microsoft Excel. Statistical analysis was 
performed using GraphPad PRISM version 6.0. Specific statistical analysis applied to data 
sets is explained within the specific experimental chapters. A p<0.05 is considered 
statistically significant. 
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3 Chapter 3: Novel Thienopyridines as modulators of platelet 
function. 
 
3.1 Introduction 
Platelet hyperactivity is often a major contributory factor in the development of 
disorders such as acute coronary syndrome (ACS) and also stroke due to acute arterial 
thrombosis. Myocardial infraction (MI) and stroke are currently the two most common 
causes of morbidity in the developed world (Zetterberg and Svensson, 2016). Thus, the 
ability to control platelet activity and reduce adverse arterial thrombus formation is a 
critical tool in modern clinical practice.  
 
Due to the importance of P2Y12 in platelet activation, P2Y12 inhibitors have been 
developed which bind to the receptor, thereby blocking the binding of ADP. Indeed, a 
combination treatment of a P2Y12 inhibitor and a COX-1 inhibitor, most commonly 
clopidogrel and aspirin (acetylsalicylic acid, (ASA)) results in reduced cardiac events in 
patients with ACS and patients having undergone percutaneous coronary intervention 
(stents) (Oh et al., 2016). Prior to FDMA approval, clopidogrel was shown to reduce the 
risk of death/MI and stroke in the CURE (Clopidogrel in Unstable angina to prevent 
Recurrent Events) and CREDO (Clopidogrel for the Reduction of Events During 
Observation) trials, and it was concluded that clopidogrel and ASA treatment had long-
term benefits (Oh et al., 2016; Emmons and Taylor, 2007; Jain et al., 2016; Li et al., 2016). 
However, ASA and clopidogrel combination treatment is usually only recommended for 
a maximum of 12 months due to the potential for gut damage and bleeding. Of those 
patients that are suitable for treatment, approximately 4%-30% will be classed as ‘non-
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responders’ (Saab et al., 2015). Currently there are several proposed reasons for 
clopidogrel poor/no response which include genetics (CYP2C19*2 loss of function allele, 
P2Y12 receptor gene polymorphism), drug interactions, (e.g. Paclitaxel, Statins, Ca2+ 
channel blockers), patient body mass index and co-morbidities such as Diabetes, 
intestinal conditions and impaired renal function (Damman et al., 2012; Bouman et al., 
2010; Fontana and Reny, 2008; T. Gremmel et al., 2011; Hulot et al., 2006; Kim et al., 
2016; Angiolillo et al., 2009; Shinoda et al., 2016).  
 
Prasugrel and cangrelor are newer thienopyridine-type drugs with an improved efficacy 
but at the cost of an increased bleed risk, with the JUMBO-TIMI (Joint Utilization of 
Medications to Block Platelets Optimally – Thrombolysis in Myocardial Infarction) study 
finding significantly more bleeding events in patients taking prasugrel compared to 
patients taking clopidogrel (Nikolaus and Robert, 2012; Damman et al., 2012). However, 
in a randomised trial, Kim et al. found that prasugrel, was able to overcome the poor 
outcome for the CYP2C19*2 loss-of-function allele seen in some clopidogrel non-
responders (Kim et al., 2016). This suggests that refinement of this family of compound 
may be useful in these patients. 
 
More recently, the synthesis of structurally related thienopyridines have been reported 
and found to have potent phospholipase C (PLC) inhibitory activity, while under 
investigation for their anti-cancer properties. To date, the anti-platelet properties of 
these thienopyridine derivatives has not investigated on platelets. 
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Our collaborators at the University of Auckland, New Zealand, synthesized six novel 
thienopyridine derivatives, displaying various sized and functionalized cycloalkyl rings as 
well as various substitutions on the phenyl ring (Table 3.1). All compounds were 
obtained as pure solids after recrystallisation from methanol and their structures were 
confirmed using NMR and mass spectrometry.  
 
The aim of this chapter was to assess the anti-platelet activity of these novel 
thienopyridines in comparison with the standard treatment, clopidogrel, by analysing 
platelet activation and platelet function following treatment with the compounds and 
stimulation with a platelet agonist. This would determine whether these novel 
derivatives have potential for future development for use in patients who have shown 
resistance to the standard anti-platelet drugs. 
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3.2  Methods 
3.2.1 Ethics 
See section 2.2 for information on ethical approval and patient recruitment. 
This section of the study involved a total of eleven participants (n=3 male, n=8 female, 
age range 20-38). Samples from some participants (chosen at random) were used for 
analysis of multiple markers of platelet activation and function. 
 
3.2.2 Sample collection and platelet-rich plasma purification 
Blood was collected and platelet-rich plasma purified as described in section 2.3. 
 
3.2.3 Thienopyridine treatment 
Thienopyridine treatments were performed as described in section 2.5. Clopidogrel 
active metabolite (Sigma, UK), thienopyridines or vehicle control (DMSO) were used at 
a final concentration of 10 µM for 30 min at 37 °C. ASA (Sigma, UK) was used at a final 
concentration of 30 µM. 
 
3.2.4 Platelet activation analysis 
Platelet activation was assessed via flow cytometry analysis of CD62P and PAC1 using a 
PE-conjugated anti-human CD62P and a FITC conjugated PAC-1 (both (BD Biosciences, 
UK) as described in section 2.6 ADP (Labmedics, UK) was used as the agonist at a 
concentration of 10 µM). 
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3.2.5 Light transmission aggregometry 
Platelet aggregometry was performed on drug-treated platelets as described in section 
2.7 ADP and Collagen were used as agonists at final concentrations of 10 µM and 1 µg/ml 
(Labmedics, UK) respectively. 
 
3.2.6 Platelet-leukocyte aggregate analysis 
Platelet leukocyte aggregates were analysed as described in section 2.6 PE-conjugated 
anti-human CD45 and FITC-conjugated anti-human CD42b (both BD Biosciences, UK) 
were used to identify leukocytes and platelets respectively in while blood.  
 
3.2.7 Statistical analysis 
Student t-tests for paired data were used to compare CD62P, PAC1 and MaxA values in 
drug-treated samples with that in control samples. * represents p < 0.05, ** represents 
p < 0.01, *** represents p < 0.001 when comparing with control. 
ψ represents p < 0.05, ψψ represents p < 0.01, ψψψ represents p < 0.001 when 
comparing drug-treated samples with clopidogrel treated samples by paired t-test. 
In ASA synergy experiments, t-tests for paired data were used to compare 
thienopyridine-only treated samples or ASA-treated samples with thienopyridine-ASA 
combination treated samples, and also each thienopyridine-ASA combination treated 
sample with clopidogrel-ASA treated samples. ɸ represents differences between 
combination treated samples and clopidogrel+ASA treated samples. 
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3.3 Results  
3.3.1 Novel thienopyridines inhibit ADP-stimulated platelet activation 
The expression of CD62P (P-selectin) along with PAC1 binding as markers of platelet α-
granule secretion and fibrinogen receptor activation respectively were analysed in PRP 
samples following treatment with the thienopyridine compounds. The PRP was 
stimulated with ADP in order to induce platelet activation and hence expression of the 
two markers. Samples were treated with clopidogrel (active metabolite), thienopyridine 
or vehicle control for 30 min prior to ADP stimulation. All novel thienopyridines resulted 
in a significant decrease in CD62P expression when compared to ADP-stimulated 
controls (Fig 3.1A). When PAC1 binding was analysed, all six thienopyridines resulted in 
inhibition, while clopidogrel was unable to produce the same effect. More interestingly, 
three of the six thienopyridines (DJ0171, DJ0097 and DJ0199) were able to inhibit the 
expression of CD62P and PAC1 binding to a greater degree than clopidogrel (Figs 3.1A & 
3.1B). In the case of PAC1 binding, this was also true of DJ0206, DJ00221 and DJ0081. 
Thienopyridine DJ0199 appeared to be the most superior compound at causing this 
effect. Taken together, these data show that the novel thienopyridines inhibited platelet 
activation in the presence of ADP and, under these conditions, were more effective than 
clopidogrel. 
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Figure 3.1 Change in CD62P (A) and PAC-1 (B) expression in ADP-
stimulated PRP following thienopyridine treatment was assessed 
by flow cytometry. Change in expression (i.e. inhibition) relative 
to control was determined. Data are presented as Mean ± SEM of 
four independent blood donors, n = 4. Statistical analysis was 
performed using the Student’s t-test for paired data to determine 
differences from control and from clopidogrel-treated samples. 
Significant differences from control (*) and clopidogrel (ψ) are 
indicated. 
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3.3.2 Novel thienopyridines inhibit ADP-stimulated platelet aggregation in 
PRP 
After assessing platelet activation, light transmission aggregometry (LTA) was used to 
assess ADP-stimulated platelet aggregation in PRP following 30 min treatment with 10 
µM of clopidogrel or the novel thienopyridines. This allowed the assessment of platelet 
function. Treatment with all six novel thienopyridines resulted in a significant reduction 
in maximum aggregation when compared to vehicle-control treated PRP (Fig 3.2). A 
paired t-test, to compare MaxA values after novel thienopyridine treatment with that 
following clopidogrel treatment, revealed that DJ0021, DJ0171 and DJ0199 caused a 
significantly greater inhibition of aggregation (p = 0.0009, p = 0.0124 and p = 0.0016 
respectively) (Fig 3.2). 
 
 
 
 
 
 
 
Figure 3.2  Change in maximum aggregation (MaxA) in ADP-stimulated PRP following 
thienopyridine treatment was assessed by light-transmission aggregometry. Change 
in aggregation (i.e. inhibition) relative to control was determined. Data are presented 
as Mean ± SEM of four independent blood donors, where n = 7. Statistical analysis was 
performed using the Student’s t-test for paired data to compare each drug-treated 
sample with the control and with clopidogrel-treated samples. Significant differences 
from control (*) and clopidogrel (ψ) are indicated. 
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3.3.3 Novel thienopyridines inhibit collagen-stimulated platelet aggregation in 
whole blood. 
Although thienopyridines block ADP-induced aggregation, an effect on collagen-induced 
activation should also be observed as the secondary wave of platelet aggregation caused 
by dense-granule-derived ADP inhibition. Indeed, the novel compounds inhibited 
collagen-induced aggregation of PRP, but to a lesser degree than ADP-induced 
aggregation (Fig 3.3). Interestingly, platelet aggregation in clopidogrel-treated samples 
was not significantly different from aggregation in the untreated samples, whilst the 
novel thienopyridines appeared more effective at inhibiting collagen-induced 
aggregation than clopidogrel, with the exceptions of DJ0206. 
 
  
Figure 3.3 Change in maximum aggregation (MaxA) in collagen-
stimulated PRP following thienopyridine treatment was assessed by 
light-transmission aggregometry. Change in aggregation (i.e. 
inhibition) relative to control was determined. Data are presented as 
Mean ± SEM of four independent blood donors, where n = 3. Statistical 
analysis was performed using the Student’s t-test for paired data to 
compare each drug-treated sample with the control and with 
clopidogrel-treated samples. Significant differences from control (*) 
and clopidogrel (ψ) are indicated. 
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3.3.4 Novel thienopyridines inhibit ADP-induced platelet-leukocyte aggregate 
formation 
Following activation, platelets may adhere to local leukocytes (monocytes and 
neutrophils) via platelet CD62P binding with P-selectin glycoprotein ligand-1 (PSGL1) on 
the leukocyte surface. Platelet-leukocyte aggregates are considered a reliable marker of 
pro-thrombotic state. Whole blood samples were pre-treated with clopidogrel, 
thienopyridine or vehicle control for 30 min prior to ADP stimulation. Samples were 
double stained with the platelet marker CD42b and the leukocyte marker CD45 and 
analysed using flow cytometry. Platelets were identified in the whole blood sample (Fig 
3.4A) by expression of CD42b and gated (Fig 3.4B). CD45-positive events within the 
platelet gate were identified (Fig 3.4C). All novel thienopyridines, resulted in a significant 
decrease in the percentage of platelet-leukocyte aggregates when compared to ADP-
stimulated controls (Fig 3.5). Statistical analyses to compare percentage of aggregates 
in the thienopyridine-treated samples with the clopidogrel-treated samples revealed a 
significant difference following treatment with DJ0097. 
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Figure 3.4 (A) Whole blood was analysed by forward scatter (FSC) and side 
scatter (SSC). (B) The platelet population was identified by expression of 
CD42b and gated (P1). (C) CD45 positive events within the platelet gate (P1) 
were identified (P2). 
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Figure 3.5 Change in the percentage of platelet-leukocyte aggregates 
within the ADP-stimulated whole blood samples following 
thienopyridine treatment was assessed by flow cytometry. Change in 
CD42b+/CD45+ events (i.e. inhibition) relative to control was 
determined. Data are presented as Mean ± SEM of four independent 
blood donors, where n =4. Statistical analysis was performed using the 
Student’s t-test for paired data to determine differences from control 
(*) and from clopidogrel-treated samples. 
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3.3.5 Novel thienopyridines show synergy with Aspirin 
Management of ACS or stroke patients often involves the use of clopidogrel in 
combination with ASA based on a duel-hit hypothesis, whereby platelet function is 
inhibited via simultaneous inhibition of the P2Y12 receptor and the COX-1 enzyme. We 
investigated the synergistic action of the novel thienopyridines and ASA, using LTA to 
assess platelet function.  
 
At the concentrations used in this study, all thienopyridines caused greater inhibition of 
platelet aggregation when compared with the inhibition caused by ASA alone (Fig 3.6) 
(represented by *). This was also true of clopidogrel. When thienopyridine-combination 
treatments were compared with the respective thienopyridine only treatments, all 
showed synergy with ASA, with the exception of DJ0206 and DJ0021 3c and 3b 
(represented by ψ). However, these thienopyridines were shown to have a significant 
inhibitory effect when used in isolation. An important facet of this work was to 
determine whether any of these novel thienopyridines were more potent when used in 
combination with ASA, than the combination of clopidogrel and ASA. It was 
demonstrated that all compounds with the exception of DJ0206 showed significantly 
greater activity than clopidogrel when used in combination with ASA (represented by 
ɸ). 
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Figure 3.6 Change in maximum aggregation (MaxA) in ADP-stimulated PRP following thienopyridine 
treatment in the presence or absence of ASA was assessed by LTA. Change in aggregation (i.e. inhibition) 
relative to control was determined. Data are presented as Mean ± SEM of seven independent blood 
donors, n=7. Statistical analysis was performed using the Student’s t-test for paired data to compare each 
drug-treated sample with the control and with clopidogrel-treated samples. * represents differences from 
ASA-only treated samples. ψ represents differences from thienopyridine-only treated samples. ɸ 
represents differences between combination treated samples and clopidogrel+ASA treated samples. 
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3.4 Discussion 
Although platelet inhibitors such as clopidogrel and, more recently prasugrel and 
ticagrelor are currently used in clinical practice, the continued platelet hyperactivity in 
some patients taking these drugs highlights a need for continued refinement of this class 
of drugs (Franchi and Angiolillo, 2015). The present study provides a significant 
contribution to the literature on P2Y12 inhibitor therapy by reporting on the use of novel 
thienopyridine derivatives and their greater activity when compared to clopidogrel. 
All six novel compounds significantly inhibited expression of both CD62P and PAC1 when 
compared to ADP-stimulated controls. When looking at the inhibition of PAC1, all the 
compounds had increased activity when compared with clopidogrel, while only DJ0171, 
DJ0097 and DJ0199 showed greater activity in the inhibition of CD62P. Although both 
CD62P and PAC1 reflect platelet activation, CD62P is expressed upon alpha-granule 
release (Blair and Flaumenhaft, 2009), while PAC1 binds to activated GP IIb/IIIa 
(fibrinogen receptor) (Shattil et al., 1985). CD62P release and fibrinogen receptor 
activation are not necessarily simultaneous events during the process of platelet 
activation (Y.A and A.V, 2003). It is therefore important to analyse more than one marker 
of platelet activation when examining the effects of anti-platelet drugs. In the present 
study, clopidogrel had a very small effect on PAC1 binding, with all six novel 
thienopyridines showing greater efficacy. This difference is likely to be highly important 
in vivo.  
 
Aggregometry was used in this study to assess platelet function. All the thienopyridines 
were found to inhibit ADP-induced platelet aggregation, with DJ0021, DJ0171 and 
DJ0199 showing greater efficacy than clopidogrel. Furthermore, collagen-induced 
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aggregation was also hindered to some degree following derivative treatment, 
highlighting the importance of P2Y12 in secondary activation from dense-granule-
derived ADP. LTA is a gold standard measure of platelet function and is included in the 
majority of studies focusing on anti-platelet drugs (Bouman et al., 2010; Armstrong et 
al., 2011; Valenti et al., 2015). However, strong platelet activation can occur without 
significant end-point aggregation and, activated platelets even with poor aggregation 
will still exert a systemic effect, increasing inflammation and stimulating further platelet 
activation (Vistoli et al., 2014). Therefore, it is critical to monitor both activation status 
and aggregation to assess the global effects of anti-platelet drugs. 
 
Platelet-leukocyte aggregate formation has been shown to be increased in patients with 
ACS (Mark I. Furman et al., 1998; Ott et al., 1996; Sarma et al., 2002) and has been 
suggested as a monitoring tool for risk of MI in these patients (M. I. Furman et al., 2001). 
Platelet-leukocyte aggregates have also been suggested to be a superior marker of 
platelet activation when compared with CD62P expression (Michelson et al., 2001). The 
data presented here shows that all six novel thienopyridine derivatives, as well as 
clopidogrel, were able to inhibit ADP-induced platelet-leukocyte aggregate formation. 
This is in agreement with similar studies that report decreases in platelet-leukocyte 
aggregate formation following clopidogrel, prasugrel or cangrelor treatment, both in 
vitro and in vivo(Thomas Gremmel et al., 2013; Harding et al., 2006; Klinkhardt et al., 
2003; Klinkhardt and Harder, 2005). 
 
Exploring synergy of the novel thienopyridine derivatives with ASA revealed that platelet 
aggregation was inhibited to a greater extent when any of the novel compounds were 
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used in combination with ASA, when compared with ASA or derivative alone. The 
exception to this was DJ0021  which although appeared to show greater efficacy when 
used as part of the combination treatment, statistical analysis proved this to be 
insignificant. More interestingly, when combined with ASA, all thienopyridines, with the 
exception of DJ0206, showed a greater inhibitory effect than clopidogrel+ASA. These 
data support results which demonstrate a superior platelet-inhibitory effect of 
clopidogrel+ASA compared to either treatment alone (Moshfegh et al., 2000; 
Serebruany et al., 2003). Armstrong et al. studied the combination of prasugrel and ASA 
on platelet activation in vitro and reported that ASA did not significantly increase the 
inhibitory effect of prasugrel (Armstrong et al., 2011). It was proposed that in the 
presence of strong P2Y12 receptor blockade, ASA does not provide any benefit. However, 
our novel derivatives were extremely effective at P2Y12 receptor blockade when used in 
isolation, and yet were enhanced by ASA. There is a lack of literature documenting the 
effects of prasugrel/cangrelor and ASA in vivo, but it appears that ASA-thienopyridine 
synergy is P2Y12 inhibitor-specific. 
 
It is clear that despite being structurally related molecules, some thienopyridines have 
greater activity than others. Indeed, prasugrel, clopidogrel and cangrelor all affect 
platelet function to varying degrees in different patient groups (Harrington et al., 2009; 
Jia et al., 2015; Roe et al., 2012; Wiviott et al., 2006). These novel derivatives follow this 
pattern and although this study has shown that all of them have the ability to inhibit 
activation and aggregation to some degree, some demonstrated greater activity. Taken 
together, these data show that DJ0171 and DJ0199 are very effective platelet inhibitors. 
They are both more effective than clopidogrel at inhibiting the expression of CD62P and 
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PAC1 in response to ADP stimulation. They are more effective at inhibiting platelet 
aggregation both alone and in combination with ASA. This global reduction in both 
platelet aggregation and activation highlights these molecules as worthy of further 
investigation to determine their potential as P2Y12 inhibitors in the clinical setting such 
as western blot to test platelet signaling.  
 
When comparing the molecular structures of the tested thienopyridines the most 
consistently active compound, DJ0171, has a strong similarity to clopidogrel with both 
containing a 2-chlorophenyl moiety linked to a larger heterocyclic group. This similar 
motif of a 2-substituted phenyl group is also found in the commonly used drug prasugrel.  
The active compound DJ0199 interestingly does not contain a 2-substituent on its phenyl 
ring. This suggests that alternative substitution patterns in these series of compounds 
can still lead to viably active compounds.  
 
Of course, when considering any drug aimed at inhibiting platelet function, it is 
important to consider over-effectiveness, with risk of bleeding becoming an issue. 
Indeed, the superior activity of prasugrel over clopidogrel has also been associated with 
increased risk of bleeding in some studies (Damman et al., 2012; Nikolaus and Robert, 
2012; Wiviott et al., 2007). It will be important to determine whether our derivatives are 
also associated with increased bleed risk in vivo. 
 
In conclusion, the six derivatives tested all possessed anti-platelet activity, showing 
inhibitory effects on ADP-induced CD62P expression and PAC1 binding, platelet-
leukocyte aggregate formation and aggregation. The work highlights the potential of 
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these compounds as alternative treatments in platelet hyperactivity-associated 
disorders. 
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4 Chapter 4: Examining the mechanism of action of novel 
Thienopyridines. 
 
4.1  Introduction 
Platelets are normally in a resting state and become activated at the site of vascular 
damage. This follows exposure to adhesive proteins expressed by endothelial cells such 
as collagen and VWF or by release of agonists such as ADP, Thrombin or TXA2 from 
neighbouring platelets that are already in an activated state (Li et al., 2010). As 
mentioned previously in section 1.5, platelet signalling involves three stages; (1) 
Interaction between the agonist and its corresponding receptor (2) activation of specific 
signalling pathways that may include downstream signalling for more than one 
extracellular receptor, and (3) inside- outside signalling (Bye et al., 2016). Many of the 
initial signalling pathways converge to activate the same set of protein kinases, yet 
further upstream, binding of specific agonists to specific receptors initiates a distinct set 
of signalling events (Bye et al., 2016). Thus, understanding this network of signals is 
important for investigating platelet function and developing new antiplatelet drugs for 
cardiovascular disease patients. The current treatments for cardiovascular patients are 
targeting the P2Y12 receptor due to its importance in platelet activation. ADP is a natural 
agonist for P2Y12 and it is stored in dense granules of platelets that release ADP as a 
positive feedback when the platelets have been stimulated by other agonists such as 
Thrombin, Collagen or TXA2. Therefore, the P2Y12 receptor plays a pivotal role in 
platelet activation and aggregation.  
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Studying the key regulators of intracellular platelet signalling such as cytosolic 
phospholipase C (cPLC ), Phosphatidylinositol 3-Kinases (PI3K) and protein kinase C 
(PKC), and also key kinases downstream of these such as PLCγ2, Vasodilator stimulation 
Phosphoprotein (VASP), Akt (Known also Protein Kinase B) and cPLA2, in response to 
platelet inhibitors is important to fully understand the global effects on platelet 
activation and function (Gibbins et al., 2004). 
 
VASP signaling is extremely useful to measure in any investigation of platelet 
function/inhibition (Hezard et al., 2005). It is a substrate cyclic adenosine 
monophosphate- (cAMP) and guanosin monophosphate (GMP)-dependent protein 
kinase (Pampuch et al., 2006) involved in the inhibition of agonist-
induced platelet aggregation. Upon stimulation of P2Y12, there is suppression of adenyl 
cyclase via Gi-protien, and inhibition of cAMP production. Therefore, ADP inhibits PGE1-
induced VASP phosphorylation. Once a P2Y12 inhibitor is added into the system, there 
is a lack of inhibition to PGE1-induced VASP phosphorylation. Therefore, the better the 
P2Y12 inhibitor, the more VASP phosphorylation is observed  (Aleil et al., 2005). VASP 
analysis was included in this study to investigate the effect of novel thienopyridine 
treatments which may work as specific blockers for P2Y12 receptor through a similar 
mechanism to clopidogrel, another member of thethienopyryidine family. 
 
Another signaling molecule analysed in this study is Akt which is a signal molecule 
downstream of the PI3K isoform (Kim et al., 2004). Thrombin has been reported to 
increase the activity of Akt1 by phospholipase β2-dependent through Ca2+ dependent 
PKc subtype (Kroner et al., 2000). It has been reported that stimulation of the Gi signaling 
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pathway by ADP leads to activation/phosphorylation of Akt in platelets (Kim et al., 2004). 
However, although P2Y12 was once thought to be critical for Akt activation, more recent 
data demonstrated that Akt phosphorylation can occur via both ADP/P2Y12/Gi-
dependent and ADP/P2Y12/Gi-independent mechanisms (Xiang et al., 2010). 
Nevertheless, assessment of the degree of Akt phosphorylation in the presence of P2Y12 
inhibitors would be a useful indicator of efficacy – higher platelet activity should be 
reflected by greater Akt phosphorylation.  
 
Cytosolic phospholipase A2 (cPLA2) is another important signaling molecule thought 
primarily to act downstream of the Thrombin receptors PAR-1 and PAR-4 (and to a lesser 
extent GPVI) (Shankar et al., 2006). Phosphorylation of cPLA2 results in release of 
arachidonic acid (AA), ADP release from dense granules and ultimately platelet 
aggregation. However, these is some evidence to suggest that activation of cPLA2 may 
in fact occur after P2Y2 stimulation. Cristofer et al (1989) have demonstrated that ADP 
treatment of platelets can stimulate Na+ /H+ exchange, increasing cystolic pH, which in-
turn leads to an increase in Ca2+ and activation of cPLA2. Moreover, it has been reported 
that Ethyllisorpopylamilorode, an inhibitor of Na+ /H+ exchange decreases pH and 
blocks ADP-induction of cPLA2 (Puri et al. 1998). A better understanding of the effect of 
P2Y12 inhibitors on activation status of cPLA2 would be a useful contribution to 
knowledge. 
 
PLCγ2 is one isoform of the PLC family which is important in platelet activation (Mangin 
et al., 2003). PLCγ2 is activated downstream of immunoreceptor tyrosine-based 
activation motif (ITAM)-bearing adhesion receptors, namely GPVI-FcRc/FccRIIA and C-
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type lectin receptor 2 (CLEC-2). As a result, collagen is the platelet agonist mainly 
responsible for activating PLCγ2. Collagen and fibrinogen toegther can also activate 
PLCγ2 via α2β1 and αIIb β3 respectively (Bye et al., 2016). Although there is evidence that 
ADP itself can activate PLCγ2, albeit with weaker effect that collagen, this has been 
shown to be via binding of ADP to P2Y1 paired with Gq, (Kunapuli et al., 2003; Gibbins et 
al., 2004). As P2Y12 activation is not involved in signaling via PLCγ2, it seemed useful to 
analyse PLCγ2 activation in the presence of the novel thienopyridines to examine 
specificity of the agents for P2Y12. 
 
Taken together, understanding the mechanism of activation of intracellular signals in 
platelets such as VASP, PLCγ2, Akt and cPLA2 following P2Y12 engagement, is important 
to determine the effects of antiplatelet drugs such as novel thienopyridines at the 
protein level. This study investigates the effect of thienopyridine treatment on 
downstream signalling events involving VASP, PLCγ2, PLA2 and Akt, with the aim of 
elucidating the target pathways of the treatment.  This will expand on the work of 
chapter 3 which showed that thienopyridines inhibit end-point platelet activation and 
aggregation. 
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4.2 Materials and Methods 
4.2.1 Sample preparation  
Samples were prepared as described in chapter 2 (section 2.3 & 2.4). Both PRP and 
washed platelets were used in this section of the study. Briefly, PRP samples were 
obtained by centrifugation of whole citrated blood for 180 g for 15min. The PRP was 
aspirated from the top of the sample and resuspended in Tyrode’s buffer (see section 
2.3 For recipe). Washed platelets were obtained by isolation of the PRP as described, 
followed by addition of 7 nM Prostaglandin E1 (PGE1) to maintain platelet inactivity 
during a further centrifugation step at 1400 g for 10 min. The platelet pellet was then 
resuspended in Tyrode’s buffer containing 7nM PGE1. 
 
4.2.2 Platelet Aggregation 
Platelet aggregation was assessed using light-transmission aggregometry, as described 
in section 2.7. 
4.2.3 Flow Cytometry Assessment of Ca2+ Flux 
Intracellular Ca2+ spiking  following stimulation with platelet agonists was assessed using 
flow cytometry as described in section 2.8. 
 
4.2.4 Western blotting  
Western blotting for phosphorylated VASP (pVASP), total VASP (VASP), phosphorylated 
Akt (pAKT), total Akt, phosphorylated PLCγ2 (pPLCγ2) and phosphorylated cPLA2 was 
performed using methods described in section 2.11. Initially PRP samples that had been 
 97 
used in the aggregation experiments were used for the western blotting. These samples 
had undergone 5 minutes ADP-stimulated aggregations in the Aggregometer prior to 
obtain the platelet lysate by addition of RIPA buffer. Further experiments involved 
washed platelet preparations rather than PRP. However, there were concerns that 
signalling events had already occurred during the 5 minutes aggregation step and so 
later experiments involved protein extraction immediately following addition of ADP, 
rather than following a 5 minutes incubation to ensure that platelet signaling events 
were not missed.  
 
Briefly, following addition of the 10 µM ADP to the sample (PRP or washed platelet 
preparation), the sample was immediately centrifuged at 1500 g for 5 minute. A 200 µl 
volume of RIPA buffer was added to the sample containing a 1:1000 dilution of both 
phosphatase and protease inhibitors to protect platelet proteins from denaturation. The 
samples were vortexed and iced for 30 min. Vortexing was performed every 5 min until 
the end of the 30 min duration. Subsequently, mixtures were sonicated for 3 minutes to 
ensure the breakdown of platelet membranes; and were then frozen at -20°C until 
further analysis. 
 
Protein assays were performed prior to western blotting using the BCA Protein Assay to 
quantify the proteins in the platelet lysates prior to Western blotting to normalize lane 
loading (see section 2.11.1). 
 
For specific protein detection, the following primary antibodies were used: anti-pVASP, 
anti-pAkt, anti-pPLCγ2 and anti-pPLA2. 
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4.3  Results 
4.3.1 Effect of platelet agonists, and thienopyridines on Ca2+ flux. 
The initial aim of this part of the work was to establish a robust method for measuring 
Ca2+ flux following platelet activation. Changes in intracellular Ca2+ concentration are 
rapid, often within nanoseconds, thereby posing a challenge in analysis of such 
responses. To date, Ca2+ fluxes have been monitored by confocal microscopy, plate‐
based assays and flow cytometry, but there are inevitably gaps in the recording of the 
data, due to the addition of compounds. This comes with significant loss of detail of a 
rapid Ca2+ response. The new generation of flow cytometers allows the addition of 
platelet agonists with continuous monitoring, providing a method for dynamic Ca2+ 
measurements. 
 
Washed platelets were used for this part of the study and were loaded with Fluo-4-AM 
before treatment (or not) with thienopyridine derivatives. The samples were then 
loaded onto the flow cytometer and acquisition was started to establish a baseline 
fluorescence reading. The lack of necessity for a vacuum system with the Accuri C6 
system meant that data could be acquired for 2 minutes followed by immediate addition 
of the platelet agonist with continual monitoring of the sample. Platelets were gated 
using FSC/SSC and a baseline fluorescence in FL1-A was established (Figure 4.1A&B). 
Over the course of 5 minutes, there was no change in baseline fluorescence. It was then 
important to check whether disturbing the sample by addition of a pipette tip during 
acquisition would have an effect on the baseline readings. A washed platelet sample was 
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added to the system and the sample was mixed at 2 minutes into the data acquisition. 
As seen in Figure 4.1C, there was no effect on fluorescence over the 5 minute period. 
 
Platelet agonists were used to test Ca2+ influx using this method. A spike in fluorescence 
was seen following addition of 1 µM Thrombin and 10 µM ADP respectively at 2 minutes 
into data acquisition (Figure 4D-F), evidencing that this assay is sensitive and rapid 
enough to detect Ca2+ flux. As expected, the Ca2+ flux induced by ADP at 10µM (a weak 
agonist) was not as significant as that induced by Thrombin at 1µM (a strong agonist), 
at either concentration.  
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Figure 4.1 Comparative cytograms of Fluo-4 fluorescence versus time, following addition (or not) of Thrombin or ADP at 2 minutes into a 5 minute sample acquisition. 
(A) gating of the washed platelets in the sample by FSC/SSC. (B) baseline fluorescence of resting platelets (C) effect of mixing the sample intra-analysis, (D) addition of 
10µM Thrombin (E) addition of 1µM ADP. 
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Ca2+ flux was assessed in ADP-stimulated washed platelet samples following treatment 
with theinopyridine compounds. Treatment with cangrelor (Fig 4.2A) abrogated the Ca2+ 
response seen following ADP stimulation (Fig 4.1A). A slight increase in fluorescence was 
observed following DJ0197 (Fig 4.2B) treatment but this reduced compared ADP 
stimulation only (Fig 4.1F). DJ0199 appeared as effective as cangrelor in inhibiting ADP-
stimulated Ca2+ flux (Fig 4.2C). However, Ca2+ signaling was still functional following 
treatment with DJ0021 (Fig 4.2D). 
 
A 
 
B 
 
C 
 
D 
 
Figure 4.2 Comparative cytograms of Fluo-4 fluorescence versus time, following treatment with (A) 
Cangrelor (B) DJ0197, (C) DJ0199 (D) DJ0021 prior to addition of 10µM ADP at 2 minutes into a 5 minute 
sample acquisition. 
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4.3.2 PRP sample aggregation followed by western blotting for pVASP 
Initially VASP phosphorylation status was studied in PRP samples following treatment 
with the thienopyridine derivatives. The use of PRP for these assays mimicked the work 
carried out in chapter 3 where it was demonstrated that these drugs have the capacity 
to inhibit both platelet activation and aggregation. PRP samples were pre-treated as 
described with thienopyridines in section 2.5, simulated with ADP and then allowed to 
aggregate in the aggregometry chamber for 5 minutes before samples were lysed with 
RIPA buffer to produce protein extracts in which the protein could be quantified, and 
the pVASP be analysed by western blot. Figure 4.3 shows the effects of these 
thienopyridine derivatives on the aggregation (A), and the levels of pVASP (B) in the 
corresponding samples. The fold difference in pVASP expression compared with control 
was calculated using densitometry, where pVASP bands were normalized against their 
relative β-actin density and then compared with the band intensity of the resting 
(unstimulated) platelet sample. As demonstrated previously, all six novel 
thienopyridines inhibited the aggregation in response to ADP to a greater degree than 
clopidogrel, and to an almost comparable level as the reversible P2Y12 inhibitor, 
Cangrelor (Fig. 4.3A). However, analysis of pVASP following aggregation revealed no 
difference between pVASP levels in resting platelet samples and activated platelets 
(stimulated with ADP) despite a seemingly increased expression of pVASP following 
thienopyridine treatment. Another notable anomaly is the lack of effect of Cangrelor on 
pVASP levels despite the strong inhibitory effect on aggregation.  
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4.3.3 Use of washed platelet preparations for aggregation followed by 
Western blotting for pVASP  
It was proposed that the use of washed platelet preparations may be more appropriate 
than PRP for western blot analysis to prevent interference from plasma proteins. The 
experiments were therefore repeated using washed platelet preparations, pre-treated 
with the compounds and stimulated with ADP for 5 minutes. Figure 4.4 shows the effects 
of these thienopyridine derivatives on the aggregation (A), and the levels of pVASP (B) 
in the corresponding washed platelet samples. Stimulation of the samples with ADP 
resulted in a reduced level of pVASP (VASP dephosphorylation) in comparison with 
pVASP levels in resting platelets, verifying that the western blotting method for analysis 
of pVASP is valid. Although high levels of pVASP were observed in the sample pre-
treated with Cangrelor, samples that were pre-treated with other thienopyridine 
derivatives did not show consistently high levels of pVASP, suggesting that they had not 
inhibited platelet activation, despite the inhibition shown by aggregometry.  
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Figure 4.3 (A) Platelet aggregation in PRP samples following incubation with 300 µM Thienopyridine treatment for 30 minutes at 37 °C and stimulated with 10 µM ADP. 
(B) Fold difference of the intensity of pVASP from the resting control by western blot. (C) Western Blot analysis of pVASP from aggregated samples and lysis by RIPA 
buffer. Beta actin was used as the loading control n=1. 
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Figure 4.4 (A) Platelet aggregation in washed platelet preparations following incubation with 300 µM thienopyridine treatment for 30 minutes at 37°C and 
stimulated with ADP. (B) Fold difference of the intensity of pVASP from the resting control. (C) Western Blot analysis of pVASP from aggregated samples and lysis 
by RIPA buffer. Beta actin was used as the loading control n=1. 
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4.3.4 Immediate lysis of washed platelet preparations. 
Although pVASP levels were maintained in cangrelor-treated samples following stimulation with 
ADP and a 5 minute aggregation, there was concern that early signalling events may be missed. 
Therefore the next experiments involved pre-treating samples with thienopyridine derivatives 
prior to stimulation with ADP and immediate lysis using RIPA buffer. 
 
Ticagrelor is a reversible inhibitor of P2Y12, currently prescribed for patients following a 
myocardial infarction who are at risk of further events. Pre-clinical and clinical data have 
demonstrated that inhibitory action of this drug on platelet aggregation also platelet signalling. 
As cangrelor is currently not in clinical use within the UK, and data surrounding its action on G-
protein mediated signaling events have not been fully identified, ticagrelor was used in the 
following experiments to confirm that the methods for platelet lysate extractions and western 
blotting were valid.  
 
Figure 4.5 illustrates the dose dependent inhibitory effect of ticagrelor on platelet aggregation 
(A). In line with these findings, the pVASP level was found to be elevated in a dose dependent 
manner (B). These data confirm that pVASP can be accurately analysed in washed platelet 
preparations using this method. The de-phosphorylation of VASP following treatment with the 
six novel thienopyridines in the previous experiment may be due to inhibition via a different 
platelet signalling pathway. It is important to explore other G-protein mediated events in these 
treated samples to fully understand the effects of these compounds. 
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Although pVASP levels were maintained in ticagrelor-treated samples following stimulation with 
ADP and a 5 minutes aggregation, there was concern that early signalling events may be missed. 
This was also supported by the data from the Ca2+ flux experiments that showed increased 
intracellular Ca2+ levels within seconds following stimulation with ADP (section 4.3.1). Therefore 
the next experiments involved pre-treating samples with thienopyridine derivatives prior to 
stimulation with ADP and immediate lysis using RIPA buffer. 
 
In order to limit activation of platelets during sample preparation, PGE1 was added to the samples 
during the preparation of washed platelets. Samples were then incubated with thienopyridine 
derivatives and then stimulated with ADP before immediate lysis with RIPA buffer. Figure 4.6 
shows that pVASP levels in samples pre-treated with DJ0206, DJ0081 and DJ0021 did not appear 
different from those in the activated platelets, however, higher pVASP levels were observed in 
those samples pre-treated with DJ0171, DJ0097 and DJ0199 indicating lower platelet activation 
in these samples. This experiment was repeated to check the reliability of this method and the 
results showed it is a reliable experiment. Fig 4.6C shows the average pVASP fold difference in 
band intensity of six repeated experiments that approved these three treatments (DJ0171, 
DJ0097 and DJ0199) resulted in a lower platelet activation compared to othervcompounds.
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Figure 4.5 (A) Platelets aggregation of washed platelet samples following incubation with different concentrations of Ticagrelor for 5 minutes at 37oC and 
stimulation with 10 µM ADP. (B) Fold difference of the intensity of pVASP from the resting control. (C) Western Blot analysis of pVASP from aggregated samples 
and lysis by RIPA buffer. Beta actin was used as the loading control n=1. 
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 Figure 4.6 (A)  Fold difference of the intensity of pVASP from the resting control of washed platelets incubated with 300 µM Thienopyryidine treatments and stimulated 
with ADP. (B) Western Blot analysis of pVASP from aggregated samples and lysis by RIPA buffer. Beta actin was used as the loading control.  (C) Average fold difference of 
pVASP from the resting control of washed platelets incubated with Thienopyridine treatments stimulated with ADP n=6 
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4.3.5 Western blot analysis of phosphorylated Akt, PLCy2 and PLA2.  
The effects of these thienopyridine treatments on other G-protein mediated signalling 
events were also assessed by western blotting. Downstream signalling of P2Y12 includes 
phosphorylation of cPLA2, AKT and PLC (Puri, 1998; Mangin et al., 2003; Kim et al., 2004). 
The isoform of PLC activated following stimulation with particular agonists is unclear, 
with suggestions that collagen mediated activation activates PLCy2, while ADP 
stimulates PLCβ (Stalker et al., 2012). However, there are contradictions in the literature 
surrounding this. PLC hyrdrolizes PIP2, producing the second messenger inositol-1,4,5-
trisphosphate (IP3) which is needed to raise the cytosolic Ca2+ concentration. The 
theinopyridines were shown to inhibit this Ca2+ flux and therefore must have an 
inhibitory effect on PLC. 
 
Following platelet Gi-coupled P2Y12 receptor stimulation, the subunits of Gi protein 
(αGi and βγ) are released. The βγ subunit can suppress protein kinase C but activate the 
phosphatidylinositol 3-kinase (PI-3K), which is responsible for both Akt and Rap1b 
regulation by phosphatidylinositol-dependent kinase-1 (PIDK1). The generated Akt, as 
well as Rap1b, contributes to activation of the platelet fibrinogen receptor, resulting in 
platelet aggregation (Joo, 2012). 
  
Another event following ADP-mediated activation, is the phosphorylation of cPLA2 due 
to the mobilised Ca2+ from the platelet dense tubular system. This causes the contents 
of platelet granules to be secreted and the platelet fibrinogen receptor to be activated. 
Activating cPLA2 also leads to form AA by splitting the fatty acids, particularly 
phosphatidylethanolamine and phosphatidylcholine, at the sn-2 position. The platelet 
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PTGS1 (also called cyclooxygenase 1 (COX-1)) enhances the conversion of AA into the 
cyclic endoperoxide prostaglandins (PGG2 and PGH2), that are transformed into TBXA2 
by TBXA synthase, leading up to amplified aggregation of the platelet (Stassen et al., 
2004). 
 
To confirm the effects of P2Y12 stimulation and inhibition on cPLA2 phosphorylation, 
washed platelets pre-treated with ticagrelor (or with untreated control), were 
stimulated with ADP and the results (Fig. 4.7A) show ticagrelor inhibit platelet 
aggregation then the samples were immediately lysed using RIPA buffer. As shown in 
Figures 4.7 B and 4.7C, ADP stimulation resulted in an increase in phosphorylated cPLA2. 
However, ticagrelor was able to prevent this increase in a dose-dependent manner (Fig. 
4.7B and C).  
 
The phosphorylation status of cPLA2, Akt, and PLCγ was assessed in washed platelets 
pre-treated with thienopyridine derivatives and stimulated with ADP followed by 
immediate lysis in RIPA buffer. Figure 4.8 shows the expression of pAkt (A&B), p-cPLA2 
(C&D) and p-PLC-γ2 (Fig. 4.9A&B) in these treated samples. The first observation, is that 
stimulation of platelets with ADP resulted in an increase in pAkt (Fig. 4.8A) in comparison 
with resting platelets, which is confirmation of previous literature. Cangrelor prevented 
this stimulation, highlighting its inhibitory effect on platelet activation. However, the 
thienopyridine derivative-treated samples showed elevated levels of pAkt which is in 
contrast to their inhibitory effects on aggregation. 
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Following ADP-induced activation, cPLA2 is phosphorylated to p-cPLA2, which in turn 
releases arachidonic acid (AA) for the biosynthesis of prostaglandins and thromboxanes 
via the cyclooxygenase system (Gibbins et al., 2004). 
 
Figure 4.8C shows an increase in pcPLA2 following stimulation with ADP, in comparison 
with resting platelets which demonestrates the effect of ADP on cPLA2. However, 
cangrelor did not show the inhibitory effect on pcPLA2 despite of cangrelor effect on 
P2Y12 receptor which is ADP receptor on platelets. This may open a gate of the other 
effect of ADP on pcPLA2 through different receptors which could be P2Y1. Moreover, 
thienopyridine treatment did not show obvious effects on pcPLA2 compared to 
stimulated platelets.  
 
pPLC γ2 (Fig. 4.9A) appeared unaffected by thienopyridine treatment when compared 
to the resting platelets when they have pre- treated with thienopyridine.  However, 
pPLCy2 seems to not  to be a downstream signal to the ADP receptor as the stimulated 
platelet not change when  or increase in compare to resting platelet. 
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Figure 4.7 (A) Fold difference of the intensity of pcPLA2 from the control. (B  ) Westren Blot bands of pcPLA2 from aggregated samples and lysis by RIPA buffer where 
Beta actin used as loaded control (C)  Platelet aggregation of PRP samples that incubated with different concentration of Ticagrelor for 5 minutes at 37 ˚C and 
stimulated with 10 µM ADP n=1. 
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Figure 4.8 (A) Fold difference of the intensity of pAkt from the resting platelets that incubated with 300 µM of Thienopyryidine treatments. (B) Westren 
Blot bands of pakt from incubated platelets and lysis by RIPA buffer where total Akt used as loaded control. (C) Fold difference of the intensity of pPLA2 
from the resting platelets that incubated with 300 µM of Thienopyryidine treatments. (D) Western Blot bands of pPLA2from incubated platelets and lysis 
by RIPA buffer where total PLA2 used as loaded control n=2. 
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Figure 4.9 (A) Fold difference of the intensity of pPLCy2 from the resting platelets that incubated with 300 µM of Thienopyryidine treatments. (B) Westren Blot 
bands of pakt from incubated platelets and lysis by RIPA buffer where total PLCy2 used as loaded control n=1.
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4.4 Discussion. 
Despite ADP being a weak agonist compared to thrombin and collagen, it is important 
in the recruitment of additional platelets to sites of injury (Dorsam and Kunapuli, 2004). 
When ADP is added to platelets in-vitro it causes TXA2 formation, protein 
phosphorylation, increased Ca2+ influx, shape change and platelet aggregation (Gibbins 
et al., 2004). As the P2Y12 receptor is important in ADP functions, blocking this receptor 
by  ticagrelor, cangrelor, or clopidogrel is important to control thrombosis in 
cardiovascular diseases, demonstrated to be clinically effective in the prevention of 
myocardial infraction, ischemic stroke and vascular death (Nurden et al., 2001; Dorsam 
and Kunapuli, 2004). Moreover, downstream signalling from the P2Y12 receptor is Gi  
signalling which leads to a reduction in the level of cAMP, activation of PI3K, Akt and 
Rap1b and influx potassium channels (Dorsam and Kunapuli, 2004; Shankar et al., 2004). 
 
This chapter of work started by investigating the effect of thienopyridines on Ca2+ 
signalling. The results demonstrated that real-time flow cytometry is an excellent 
method for allowing assessment of Ca2+ following addition of an agonist mid-sample 
analysis (Fig 4.1). A change in fluorescence was observed following stimulation of 
washed platelets with ADP and Thrombin. Furthermore, DJ0199 and DJ0097 (as well as 
cangrelor) were both shown to inhibit the Ca2+ response to ADP, while DJ0021 appeared 
to be relatively ineffective (Fig 4.2). However, despite these clear-cut results, a great 
deal of optimisation was involved this assay, and the sensitivity to ADP did seem to 
disappear very quickly following preparation of the samples, meaning that inconsistent 
results were obtained (data not shown). However, response to thrombin in this assay 
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was extremely consistent, and the data provide justification for adopting this assay more 
routinely in platelet signalling research.  
 
Next, phosphorylation of VASP was assessed using Western Blotting, as a marker to 
evaluate P2Y12 antagonism (Hezard et al., 2005). However, due to variability in the 
response to clopidogrel between individuals, the study utilised another positive control 
Cangrelor, as a direct reversible antagonist of P2Y12 (ADP receptor) (Hezard et al., 
2005). Studying the signal by western blot required the tested drug to have a clear 
difference between negative and positive control samples. 
 
The main finding from this study is that specific novel thienopyridines maintain the 
phosphorylation of VASP when platelets are stimulated with 10μM ADP. This 
concentration of ADP is supported by the study of Pampuch et al. (2006) who 
demonstrated the correlation of analysing VASP, LTA and flow cytometry when 
following cangrelor treatment and stimulating with 10μM ADP (Pampuch et al., 2006). 
VASP phosphorylation status has been shown to be an extremely reliable marker of 
platelet activation (Mallouk et al., 2018); (Hezard et al., 2005).  Indeed, western blotting 
analysis has been considered as a robust qualitative method (Dorsam and Kunapuli, 
2004; Hezard et al., 2005; Zhang et al., 2017). 
 
This chapter intially investigated pVASP in the same samples that had been used for 
aggregation analysis (Fig. 4.3). The samples were first tested by LTA and then lysed for 
western blot analysis. However, the results from western blots were not consistent with 
the LTA results. The proposed reason could be due to interference of other proteins in 
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the PRP samples in the test and the second reason from the delay in lysing platelets after 
aggregation assessment. 
 
To counteract these issues, platelets were incubated with thienopyridine, activated with 
ADP and lysed immediately. This technique proved successful in the study of VASP (Fig. 
4.6), Akt (Fig. 4.7A&B) and PLA2 (Fig. 4.7B&C). In contrast the study of Hezard et al., used 
PRP samples and incubated platelets with ADP or the PGE1 inhibitor for 5 minutes 
(Hezard et al., 2005). This showed the difference in platelet VASP phosphorylation  by  
PGE1 or dephosphorylation by ADP. 
 
This chapter also investigated the effect of other signaling events that may be involved 
in downstream signalling of the P2Y12 receptor, and could be affected by blocking P2Y12 
with novel thienopyridines. One such downstream signalling molecule is Akt, which is 
important in platelet activation (Kim et al., 2004). The results of this study showed 
thienopyridines did not inhibit Akt phosphorylation once platelets were induced by ADP, 
whereas cangrelor (positive control) did (Fig. 4.7A&B). The data demonstrating 
activation of Akt by ADP is supported by the study of Kim (2004) which stimulated 
platelets from mice deficient in P2Y1 with ADP. Their results showed activation of Akt 
signaling, illustrating the specificity of P2Y12 in Akt activation. In addition, Akt activation 
was inhibited in platelets from these mice which were treated with clopidogrel and 
induced by ADP. Furthermore, this demonstrates the mechanism of activating Akt by 
the Gi and P2Y12 receptor complex (Kim et al., 2004; Carrié et al., 2009). 
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Although Akt has been shown to be activated only by P2Y12, ERK has been shown to be 
activated by the presence of either P2Y1 or P2Y12. Since ERK may signal through the 
P2Y1 receptor which is not blocked by clopidogrel or cangrelor, it was not investigated 
in the present study (Garcia et al., 2007).  
 
With regards to cPLA2, the results show no effect of thienopyridine or cangrelor, despite 
ADP leading to increased expression in stimulated platelets compared to resting 
platelets (Fig. 4.7B&C). Strangely, the alternative P2Y12 inhibitor ticagrelor was shown 
to  inhibit cPLA2 in a dose dependent manner. Literature on the involvement of cPLA2 
in signalling downstream of P2Y12 is weak (Garcia et al., 2007), but  De Cristofaro et al 
(1989), reported that cPLA2 was indirectly activated following ADP stimulation due to 
the Na+ /H+-mediated increase in cystolic pH, increased Ca2+ levels (De Cristofaro et al., 
1989). Moreover, it has been reported that Ethyllisorpopylamilorode, a disrupter of Na+ 
/H+ exchange decreases the cytosolic pH which blocks ADP induction of cPLA2 (Puri, 
1998). cPLA2’s involvement in signalling following thrombin stimulation is much more 
established (Puri, 1998). As the results from the present study did not provide consistent 
results between cangrelor and ticagrelor, the role of cPLA2 in P2Y12 signalling remains 
to be determined. 
 
With regards to the PLCγ2 results from this study, ADP stimulated samples did not 
appear to show activation of PLCγ2, and neither cangrelor nor the novel thienopyridines 
had any affect (Fig. 4.9).  As mentioned earlier, the literature reports that collagen is the 
predominant activator of PLCγ2 via GPVI-mediated association of the FcRy chain 
(Watson et al., 2001). PLCγ2 works downstream from the α2β1 and GPVI receptors. A 
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study using amarogentin, an active ingredient of the Gentiania Lutea plant, 
demonstrated inhibition of platelet activation induced by collagen but not by thrombin 
or archidonic acid (Yen et al., 2014). Amarogentin was found to inhibit PLCγ2 in collagen-
stimulated platelets via PLCγ2-PKC-P47 pathway in conjunction with the MAPK signalling 
cascade (Yen et al., 2014). The work on amarogentin supports the results from this 
chapter. Collagen-induced platelet activation leads to release of secondary agonists 
such as ADP and TXA2 which then appear to be involved in PLCβ activation, another of 
the PLC isoforms (Mangin et al., 2003). This activation of PLCβ occurs through Gαq protein 
coupled receptor (Mangin et al., 2003). Moreover, platelet aggregation has been 
reported to be normal in PLCγ2 deficient mice when platelets are stimulated with ADP 
or thrombin, whereas the aggregation is abolished when stimulated with collagen. ADP 
receptor antagonists in these mice lead to inhibition of shape change when platelet 
activated by ADP (Wang et al., 2000).  
 
In conclusion, this chapter demonstrated that the novel thienopyridines DJ0171, DJ0097 
and DJ0199 were able to maintain VASP phosphorylation in the presence of ADP, with 
pVASP levels significantly higher in treated platelets than in ADP-simulated platelets. 
However, effects on pAkt, pcPLA2 and pPLCγ2 were inconsistent. The real-time flow 
cytometry assay was shown to be a robust method for analysis of Ca2+ flux in platelets. 
Further work would act to clarify the involvement of PLCβ in P2Y12 signalling, and the 
effects of these novel compounds on this protein kinase.  
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5 Chapter 5: Pilot Study – The Effect of Novel Thienopyridines on 
Endothelial Cells.  
 
5.1  Introduction  
Endothelial cells play a vital role in haemostasis, with both antithrombotic and 
prothrombotic properties that work in a balanced system to maintain blood fluidity and 
prevent thrombus formation (Wu and Thiagarajan, 1996). Cell-cell communication 
between endothelial cells with platelets has only recently begun to receive systematic 
study, but it is understood that they communicate in a paracrine fashion (over relatively-
long distances), via transient local mechanisms and through receptor-mediated cell-cell 
interactions (Siegel-Axel and Gawaz, 2007). 
 
Under normal conditions, microenvironmental nitric oxide (NO) inhibits the expression 
of cellular adhesion molecules on the endothelium, keeping the cells in a ‘resting state’ 
NO also contributes to maintaining a platelet resting state. Indeed, in the presence of 
pro-inflammatory cytokines, a much higher concentration of NO is required to prevent 
expression of adhesion molecules and recruitment of leukocytes to the local area(Liao, 
1998). Inhibition of endogenous endothelial NO production by NG-monomethyl-l-
arginine has been shown to induce the adhesion molecule VCAM-1 expression in 
cultured endothelial cells (De Caterina et al., 1995; Khan et al., 1996).  
 
In addition to its presence in platelet alpha-granules, CD62P (P-selectin) is expressed on 
the endothelial cell surface upon activation following release from Weibel-Palade bodies 
located in the cytosol (Mark I. Furman et al., 1998; Kuckleburg et al., 2011; Ley et al., 
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2011). The CD62P acts as a cell adhesion molecule, binding to PSGL1 which is found on 
various hematopoietic cells such as neutrophils, eosinophils, lymphocytes, 
and monocytes. CD62P is therefore vital in the recruitment of leukocytes to the site of 
vessel injury, and this works in conjugation with platelet-expressed CD62P which, as 
described in chapter 3, allows for the formation of platelet-leukocyte aggregates (Huo 
et al., 2003; Nofer et al., 2010; Verhamme and Hoylaerts, 2006). Levels of CD62P (along 
with another selectin CD62E) have been found to be elevated in patients with Acute 
Myocardial Infarction (AMI)  (Sakurai et al., 1997); providing justification for 
investigating changes in expression of this molecule in response to P2Y12 inhibition. 
 
CD62E (E-Selectin) is expressed only on endothelial cells following stimulation with pro-
inflammatory cytokines. It is arguably the most specific, inducible endothelial cell-
surface molecule involved in the adhesion of neutrophils, monocytes, and T cell subsets 
to the local area. Its expression has been shown to be upregulated in cases of ACS and 
atherosclerosis. Interestingly, clopidogrel has been shown to retard the development of 
atherosclerotic plaques in mouse models and to significantly reduce both CD62P and 
CD62E expression when compared to non clopidogrel treated mice (Heim et al., 2016).  
 
Intercellular adhesion molecule-1 (ICAM-1; CD54) is a 90 kDa member of the 
immunoglobulin (Ig) superfamily and is critical for the arrest and migration of leukocytes 
out of blood vessels and into the tissues. ICAM-1 is upregulated by pro-inflammatory 
cytokines on the surface of endothelial cells (Lawson and Wolf, 2009) and can be shed 
into the extracellular milieu as soluble ICAM-1) (sICAM). sICAM-1 can be detected in 
various body fluids, with elevated levels being observed in patients with atherosclerosis, 
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heart failure, coronary artery disease and transplant vasculopathy (Macías et al., 2003; 
Lawson and Wolf, 2009), indicating its association with endothelial dysfuction/over-
activation. It is proposed that ICAM-1 directly contributes to inflammatory responses 
within the blood vessel wall by itself increasing endothelial cell activation in the local 
area and augmenting atherosclerotic plaque formation and can upregulate its own 
expression via a positive-feedback loop. ICAM-1 has been shown to be over-expressed 
in human atherosclerotic lesions. There is therefore justification for looking at whether 
P2Y12 inhibitors have the ability to downregulate ICAM-1 expression on endothelial 
cells (Lopes-Virella and Virella, 1992).  
 
Vascular Cell Adhesion Molecule-1 (VCAM-1) is another cell adhesion molecule involved 
in the recruitment of leukocytes to the site of injured vessel. Unlike ICAM-1 that is 
expressed at low levels on non-activated endothelial cells, VCAM-1 is only expressed by 
endothelial cells upon activation (Granger and Senchenkova, 2010). In addition to 
sICAM-1, sVCAM-1 shed from the activated endothelial cells has been found to be 
elevated in patients with ACS when compared with healthy control patients, and 
sVCAM-1 can strongly predict an increased risk for subsequent cardiovascular events in 
such patients (Postadzhiyan et al., 2008). Again, there is justification for investigating 
the effects of P2Y12 inhibitors on the expression levels of this protein. 
Many of the platelet agonists that have been discussed and utilised throughout this 
thesis have important roles at the endothelial cell level. ADP has a significant role in 
inducing the migration of human endothelial cells via the interaction with endothelial-
P2Y1 receptor expression. This mechanism is one of several that contribute to 
angiogenesis during vascular repair (Shen and DiCorleto, 2008). Other P2Y receptor 
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family members are known to be expressed by endothelial cells. Shen et al. (2008) 
reported very high levels of P2Y1 on endothelial cells, with lower levels of P2Y12. This 
same study also demonstrated a MAPK downstream signalling cascade involving 
phosphorylation of Erk1/2, JNK, and p38 following ADP stimulation. Hess et al. (2009) 
also showed phosphorylation of eNOS following ADP treatment, thereby indirectly 
demonstrating ADP-mediated Ca2+ flux in these cells. Kaczmarek et al. (2005), 
demonstrated that ATP is also capable of inducing Ca2+ flux in this cell type. ATP has 
been shown to enhance vasodilation via the P2X4, while in vascular smooth muscle cells 
(VSMC), ATP appears to cause vasocontriction via P2X1. P2Y2 and P2Y11 have also been 
shown to be present at the mRNA level in endothelial cells (Shen and DiCorleto, 2008). 
Upon ADP stimulation, endothelial cells have been shown to release PGI2 and NO which 
act to inhibit platelet activation (Shen and DiCorleto, 2008). Thereby suggesting an 
antithrombotic role. This is in contrast to the effects of ADP on platelets themselves, but 
suggests a mechanism by which the endothelial cells limit the thrombosis to the local 
area.  
 
This chapter describes data obtained from pilot experiments, designed to assess the 
effects of P2Y12 inhibitors on expression of key adhesion molecules by endothelial cells. 
This was firstly to determine whether the endothelial dysfunction reported in patients 
with concomitant platelet hyperactivity is also being addressed by these same 
medications, and secondly to determine whether the novel thienopyridine compounds 
had such as effect. 
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5.2 Methods  
5.2.1 Cell culture  
Human umbilical vein endothelia cells (HUVEC) line was purchased from Cattag 
Medsystem (Buckingham, UK). The cells were cultured as described in section 2.9. 
 
5.2.2 Sample preparation for treatment 
Between passages 3 to 8, the HUVEC cells (4.6 x104) were used for thienopyridine 
treatments. The cells were cultured in 24 well plates over glass cover slips that had been 
coated with 0.1% gelatin. The cells were allowed to settle in the centre of the coverslips 
for 30 minutes before addition of M199 medium to avoid growing the cells at the edges 
of the well outside the cover slip. After two days, the cells were washed twice with 
phosphate buffer saline (PBS) (Lonza, UK) and incubated with low serum 5% (FBS) M199 
overnight. Thereafter, the cells were washed twice ready for thienopyridine or TNF-α 
treatments. The cells were at approximately 80% confluence on the coverslips prior to 
treatment.   
 
5.2.3 HUVEC cell treatments.  
HUVEC cells were treated with 100ng/ml TNF-α (Promo Cell, UK) for 4 hours with fresh 
media M199 with low serum FBS to avoid the interference with the treatment effect on 
cells. A 300 μM concentration of each thienopyridine treatment was applied to the cells 
for 30 minutes  at 5% CO2 at 37°C. Ticagrelor was used as the comparison. At the end of 
the treatment period, 10μM ADP was added to the samples including the untreated 
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control and incubated for 5 minutes. Cells were washed twice with PBS before fixation 
and labelling. 
 
5.2.4 Fixation and labelling 
As it described in section 2.10, The cells were fixed with 0.5% paraforlmaldehyde for 2.5 
minutes then washed with PBS. After that, the cells were permeabilised in 1% triton X-
100 for 8 minutes, then blocked using 3% bovine serum albumin (BSA) for 1 hour. The 
cells then were incubated with the following monoclonal antibodies at a 1:300 dilution: 
Mouse Anti-human P-selectin, Rabbit anti-human E-selectin, Mouse anti-human ICAM-
1 and rabbit anti-human VCAM-1. The samples were incubated overnight in the fridge 
in a dark environment. Secondary antibodies (used at a 1:400 dilution) were added: 
Alexa 568 (Rhodamine)-Anti-rabbit IgG added to all samples which was used to detect 
E-selectin in one sample and VCAM-1 in another. Alexa 647 (Cy5)-Anti-mouse IgG was 
used to detect P-selectin and ICAM in the different samples. The secondary antibodies 
were incubated in the dark for 1 hour at room temperature. The cells were then washed 
twice with PBS before 1 drop mounting media with 4,6 diamidino-2-phenylidole (DAPI) 
was added to the sample to stain the genetic material in the cells. The coverslips were 
then mounted on to glass microscopy slides. The samples were kept in the dark until 
analysis by epifluorescence microscopy (Zeiss imager Z1 microscope) under 10x and 40x 
oil immersion lens.  
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5.3 Results  
5.3.1 Effect of thienopyridine treatments on ADP-induced HUVEC cell 
expression of P-selectin and E-selectin   
TNFα was used as a positive control in this study due to the well established stimulation 
of CD62P and CD62E on endothelial cells by this cytokine. The images from the 
epifluorescence microscopy illustrate the effect of stimulators on HUVEC cells 
expression of CD62P and CD62E. 
  
High expression of P-selectin (green) and E-selectin (red) on HUVECs was observed 
following treatment with TNFα, confirming the validity of the method (Fig 5.1A). 
Treatment with ADP was also shown to induce the expression of both adhesion 
molecules (Fig 5.1B). 
 
An exciting finding was that treatment with thienopyridines resulted in absence of 
CD62P expression in ADP-stimulated HUVEC cells (Fig 5.1C and Fig 5.2 D-G). CD62P was 
also absent in the ticagrelor treated samples. This was not the case for CD62E, which did 
appear to be expressed in most samples. However, a complete absence of the protein 
was observed following ticagrelor treatment, with lower intensities also observed 
DJ0171 and DJ0199, when compared to the other treatments. 
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Figure 5.1 Epifluorescence microscopy pictures of P-Selectin (green), E-selectin (red) and DAPI (blue) in HUVEC cells following different treatments.  HUVEC cells 
were incubated with (A) TNF-α for 4 hours as positive control. (B) ADP only for 5 minutes, (C) DJ0206. (D) DJ0081. (E)DJ0021. (F)DJ0171 (G) DJ0097 H) DJ0199 and 
(I) Ticagrelor. For C-I, the cells were treated with P2Y12 inhibitor for 30 minutes prior to 5 minute ADP stimulation and investigated on 40x oil emmersion. 
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Figure 5.2 Epifluorescence microscopy pictures of P-Selectin (green), E-selectin (red) and DAPI (blue) in HUVEC cells following different treatments.  HUVEC cells were 
incubated with (E)DJ0021. (F)DJ0171 (G) DJ0097 H) DJ0199 and (I) Ticagrelor. For C-I, the cells were treated with P2Y12 inhibitor for 30 minutes prior to 5 minute ADP 
stimulation and investigated on 40x oil emersion lens.. 
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5.3.2 Effect of thienopyridine treatments on ADP-induced HUVEC cell 
expression of ICAM-1 and VCAM-1.  
TNFα was used again as a positive control in this study due to the well established 
stimulation of ICAM-1 and VCAM-1 on endothelial cells by this cytokine. The images 
from the epifluorescence microscopy illustrate the effect of stimulators on HUVEC cell 
expression of ICAM-1 (green) and VCAM-1 (red), with high expression of both adhesion 
molecules following TNFα confirming the validity of the method (Fig 5.3A). Expression 
of VCAM-1 was high in cells following ADP stimulation, yet ICAM-1 expression was 
significantly lower (Fig. 5.3B). 
  
Interestingly, all novel thienopyridines (and ticagrelor) were found to prevent ADP-
induced stimulation of VCAM-1 (Fig. 5.3C and Fig. 5.4 D-I). Obviously there was a 
notable absence of ICAM-1 expression in the theinopyridine treated cells, but this was 
no different from the ADP-only treated cells.
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Figure 5.3 Epifluorescence microscopy pictures of ICAM-1 (green), VCAM-1(red) and DAPI (blue) in HUVEC cells following different 
treatments.  HUVEC cells were incubated with (A) TNF-α for 4 hours as positive control. (B) ADP only for 5 minutes, (C) DJ0206. (D) 
DJ0081. For C-I, the cells were treated with P2Y12 inhibitor for 30 minutes prior to 5 minute ADP stimulation and investigated on 
40x oil emersion lens. 
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Figure 5.4 Epifluorescence microscopy pictures of ICAM-1 (green), VCAM-1(red) and DAPI (blue) in HUVEC cells following different treatments.  HUVEC cells were incubated 
with (E)DJ0021. (F)DJ0171 (G) DJ0097 H) DJ0199 and (I) Ticagrelor. For C-I, the cells were treated with P2Y12 inhibitor for 30 minutes prior to 5 minute ADP stimulation and 
investigated on 40x oil emersion lens. 
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5.4 Discussion 
The main finding of this pilot work is that the novel thienopyridine compounds have an 
effect on the expression of adhesion molecules by HUVEC cells, namely CD62P, CD62E 
and VCAM-1.  It has confirmed that ADP itself stimulates expression of these adhesion 
molecules, which at present is relatively unclear in the literature. The findings indicate 
that in the presence of thienopyridines, the recruitment of leukocytes to the site of 
vascular injury will be impaired (Mark I Furman et al., 1998; Nofer et al., 2010; 
Kuckleburg et al., 2011) and further indicates that for those patients currently treated 
with P2Y12 inhibitors such as clopidogrel and ticagrelor, it is not only the platelet 
responses that will be inhibited, but implies that the anti-haemostatic effects extend to 
a more global scale. Therefore, these compounds act to suppress the adhesion 
molecules that contribute to inflammation and the progression of atherosclerosis 
(Zhang et al., 2002).  
 
It has been demonstrated that ADP effects the production of PGI2 and NO, supressing 
the release of these platelet inhibitory factors from the endothelial cells (Hess et al. 
2009). Evidence also shows that ADP stimulates migration of endothelial cells during the 
process of angiogenesis and repair of injured tissue (Hess et al., 2009). However, this 
effect appears to be via interaction with the P2Y1 receptor on endothelial cells, which 
has down-stream signalling pathways involving the MAPKs ERK1/2, P38 MAPK and JNK 
(Shen and DiCorleto, 2008). Work on rats has demonstrated that clopidgrel can prevent 
vascular remodelling and has beneficial effects on the aortic endothelium in 
hypertensive rats. However, the authors report that the effects do not seem to be 
directly related to P2Y12 receptors in the vessel (Giachini et al., 2014). 
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A P2Y12-specific effect of ADP has been shown in vascular smooth muscle cells (VSMC), 
where vasoconstriction of the vessels following P2Y12 ligation has been 
observed(Wihlborg et al., 2004). Further work would explore the effects of mainstream 
P2Y12 inhibitors such as clopidogrel and ticagrelor on VSMCs and also clarify whether 
similar effects are seen following use of the novel thieopyridines. 
 
Obviously the data are preliminary and extensive further work is required to fully 
characterise the effects of P2Y12 inhibitors on endothelial cell activation and function. 
The epifluorescence analysis of adhesion molecule expression presented here provide 
qualitative data which could be supported by more quantitative methods for protein 
expression such as flow cytometry, and ELISA.  
 
The research group acknowledged the controversy surrounding the effects of trypsin on 
expression of adhesion molecule expression. The cells in this work were allowed to 
adhere to coverslips, fixed and labelled with the antibodies prior to image analysis, 
rather than employ the method used in many studies that utilises fixing and staining of 
trypsinised cells in suspension. This method was shown to be a valid method for analysis 
of E-selectin, VCAM-1 and ICAM-1 in formaldehyde fixed HUVEC monolayer cells 
(Gräbner et al., 2000). 
 
In conclusion, the study demonstrated that endothelial cells treated with ADP express 
CD62P, CD62E and VCAM-1. Treatment with ticagrelor and all six novel thienopyridines 
can inhibit the ADP-induced expression of CD62P, while DJ0171 DJ0199 and ticagrelor 
showed significant effects on CD62E. ADP did not appear to stimulate ICAM-1. All six 
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novel thienopyridines as well as ticagrlor completely prevented the ADP-induced 
expression of VCAM-1. Taken together the results point to the importance of these 
compounds in the regulation of endothelial dysfunction and the importance of further 
work in this area. 
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6 Chapter 6: Platelet roles outside of haemostasis: The cancer 
microenvironment and platelet function 
 
6.1 Introduction  
The thesis so far has focused on the role of platelets as central players in haemostasis 
and thrombosis, and looked at the potential for novel thienopyridine compounds to 
modulate both platelet and endothelial activities. 
 
However, platelets are also central players in innate immunity and inflammation 
(Morrell et al., 2014; Sabrkhany et al., 2011; Ronnlund et al., 2012; Almog and Klement, 
2010), secreting a vast array of cytokines and chemokines that orchestrate the immune 
response to infection. Factors in the platelet releasate contribute to a wide range of 
processes such as activation (CD40L, MIP-1α IL-1β), proliferation (TGFβ, PDGF), and 
chemotaxis (SDF-1, PF4) of leukocyte subsets, while others are involved in adhesion of 
platelets to leukocytes and endotheial cells (CD62P,  GPIbα, vWF) (Reviewed in Morrell 
et al., 2014). Platelets also contain more than 30 angiogenesis proteins that may 
contribute to the promotion of new blood vessel growth, particularly in the developing 
tumour. These include VEGF, bFGF, PDGF, EGF and MMPs, to name a few (Italiano et al., 
2008)  
 
This is another area for consideration when applying anti-platelet therapies, as 
inhibition of platelet signalling will also have an effect on the immunological properties 
of the platelets. Indeed recent research has shown that the P2Y12 inhibitors clopidogrel 
and ticagrelor were able to supress systemic inflammation in a human sepsis model 
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(Thomas et al, 2015). This novel work demonstrated that treatment with these P2Y12 
inhibitors was able to reduce platelet-monocyte aggregate formation and peak levels of 
major pro-inflammatory cytokines, including TNFα, IL-6 and CCL2 that were induced by 
intravenous injection of E.coli endotoxin. The work demonstrates the vital importance 
of platelets in systemic inflammation and suggests that anti-platelet therapy could be 
useful in the treatment of systemic inflammatory response syndrome (SIRS) and sepsis. 
 
Moreover, it has been found that platelets act as key mediators of tumour metastasis 
(Almog and Klement, 2010; Sabrkhany et al., 2011) . Surprisingly, patients with cancer, 
whether a solid tumour or a haematological malignancy have abnormal haemostatic 
parameters which may lead to thrombosis or active bleeding (Ronnlund et al., 2012). 
This indicates that cancer cells themselves or neo-angiogenesis processes may have an 
effect on platelet function in these patients. 
  
There is a large body of evidence demonstrating that platelets sequester many 
microenvironmental factors. This could be the reason for abnormal platelet function in 
the case of cancer patients, where the abnormal cancer cell secretome contributes to a 
large proportion of the microenvironment (Peterson et al., 2012; Nilsson et al., 2011; G. 
L. Klement et al., 2009; G. Klement et al., 2004).  Some of these factors that can be 
sequestered in platelets (Table 6.1) have been found to be cancer specific, which has led 
to great interest in analysing platelet content as an early tumour detection in cancer 
patients.  
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Table 6-1 Summary of literature evidencing the uptake of tumour-derived proteins by platelets in 
different cancers 
Author Cancer type Sequestered tumour-
derived factors by 
platelets 
Klement et al., 
2009  
Malignant animal – 
breast cancer 
VEGF  
Nilsson et al., 2011  Glioma and prostate 
cancer  
Tumour associated 
RNA (EGFRVII and 
PCA3) 
Kerr et al., 2010  Human prostate cancer 
cell 
TGF-β1, VEGF, MCP-
1,MMP-2, RANK, 
RANKL and TIMP-1. 
Fu et al., 2015 Non-small cell lung 
cancer (NSCLC) 
VEGF 
Benoy et al., 2002  Breast cancer VEGF 
Klement et al., 
2004  
Human tumour injected 
in mice  
VEGF,  bFGF, PDGF, 
BDNF, endostatin 
Peterson et al., 
2012 
Colorectal cancer  VEGF, PDGF and PF4 
Cervi et al., 2008  Liposarcoma  PF4  
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A number of studies report significant changes in cytokine profiles and growth factor 
levels in the serum of cancer patients compared with healthy people. Interestingly, IL-6, 
TNF-α and VEGF have been highlighted as those factors most commonly over-expressed 
in cancer patients. It has been suggested that tumour derived IL-6 has a role in 
controlling VEGF level in the platelets of breast cancer patients which demonstrates the 
link between the serum level of IL-6 and VEGF concentration in platelets (Benoy et al., 
2002). 
 
Other studies have reported the percentage of thrombosis and bleeding in cancer 
patients (Table 6.2). Surprisingly, it has been reported that VTE incidence in cancer 
patients is seven times higher than that in a healthy population (Falanga et al., 2013). 
In contrast, active bleeding has also been seen in cancer patients, and is considered as 
a major cause of death in 10% of solid tumour patients.
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Table 6-2 Collective evidence of haemostatic abnormalities in cancer patients. 
Author  Cancer type No. of 
patients  
Haemostatic abnormality Proposed cause of 
haemostatic 
abnormality.   
Klasters et 
al., 1972 
 
Different cancer (leukemia, 
breast and lung cancer) 
157 Severe haemorrhage - 11.4% 
died as a direct result 
Severe 
thrombocytopenia  
 Acute leukemia 27 Severe haemorrhage - 30% 
died as a direct result  
 
Falanga et 
al., 2013 
 
Myeloproliferative 
neoplasms 
NA 10%-40% Thrombosis ATE Unknown 
 HL, NHL and MM 
  
NA The highest incidence of VTE 
(thrombosis) among 
haematological malignancy 
Unknown 
Belt et al., 
1978 
 
Solid tumors  718 10.4% presented with active 
bleeding  
Multifaceted: 49.3% 
due to drug induced 
thrombocytopenia, 
33.3% due to tumor-
invasion, 9.3% due to 
DIC and 8% was not 
related to malignant 
neoplasm neither 
chemotherapy. 
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Cartoni et 
al., 2009 
 
Haematological 
malignancies (leukemia, 
lymphoma, MM, MDS, 
MPNs). 
469 23% presented with major 
bleeding 
Main reason for 
bleeding was due to 
low platelet count 
(<20×109/L). 
 Acute myeloid leukemia  69 54% presented with active 
bleeding 
 
 Blast crisis (in CML?) 56 46% presented with active 
bleeding 
 
 ALL 39 46% presented with active 
bleeding 
 
 MM 39 13% presented with active 
bleeding  
Interference of serum 
proteins with platelet 
activity and 
coagulation factors 
Caruso et 
al., 2010 
 
Lymphoma 18081 
(meta-
data) 
Incidence of thrombosis as 
6.4% 
Unknown 
 NHL 1180 7% thrombosis  Unknown 
 HL 177 5.6% thrombosis  Unknown 
Goldschmi
dt et al., 
2003 
CNS lymphoma  42  59.5% presented with VTE 
and 7% died due to VTE 
Unknown 
Table 6-2 Collective evidence of haemostatic abnormalities in cancer patients. 
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We decided to use a Hodgkin Lymphoma cell model to study the interplay between the 
cancer cell secretome and platelet function. Many cytokines are released from 
lymphoma cells at abnormal levels, such as IL-6, TNF α, IL-1β, IL-5, IL-9, M-CSF and TGF-
β1 (Hsu et al., 1993), where they seem to have a role in disease progression. It has been 
demonstrated that the level of these cytokines is higher in circulation in lymphoma 
patients compared to healthy individual (da Silva et al. 2015). 
 
Hodgkin Lymphoma is one of the most common lymphomas in the UK, with 2000 new 
cases per year (CRUK, 2016). Although, the management of this disease has improved 
with the introduction of newer treatment approaches, both thrombosis and bleeding 
are difficult to manage in these patients. The incidence rate of thrombosis in lymphoma 
patents varies between 3-13%, and can reach up to 60% in lymphoma cases with primary 
brain metastasis (Caruso et al., 2010).  
 
The aim of this part of the study was to further clarify the effect of the lymphoma 
microenvironment on platelet function via the use of Lymphoma cell lines, recombinant 
cytokines and platelets obtained from healthy individuals. 
The aim was achieved via the following objectives: 
 To investigate the effect of the Hodgkin Lymphoma cell line, L1236, secretome 
on healthy platelet activation and function. 
 To determine the effects of recombinant cytokines on healthy platelet activation 
and function. 
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6.2   Methods 
6.2.1  Specimen collection 
Blood Samples were collected from healthy volunteers in citrated vacutainers and 
PRP/PPP was isolated as described in section 2.3.  
6.2.2 Cell culture 
The Hodgkin lymphoma cell line L1236 was used in this study. Cells were routinely 
passaged and maintained in RPMI media, supplemented with 15% FBS at 370C in a 
humidified environment of 5% CO2 in air. Cell viability was assessed using the Trypan 
blue exclusion method on a haemocytometer, and experiments were only performed 
when cell viability was >95%.  
Cells, in a total volume of 3ml of the media were seeded into 6-well plates at varying 
densities as shown in table 6.3 and incubated at different incubation times. Each 
concentration was run in duplicate.  
 
 
 
Cell Conc. Incubation time 
1×105 cell/ml 24  Hours 48  Hours 72  Hours 96  Hours 
5×105 cell/ml 24  Hours 48  Hours 72  Hours 96  Hours 
1×106 cell/ml 24  Hours 48  Hours 72  Hours 96  Hours 
 Table 6-3 Cell culture concentration at different incubation times 
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Following incubation, each sample was removed from the well, centrifuged at 500 g for 
5 minutes at 22°C and the supernatant (conditioned media (CM)), was removed and 
stored for later use at -80°C.  
6.2.3 Treating platelet with conditioned media  
CMs from three different cell concentrations that were incubated for 24, 48, 72, 96 
hours, were taken from -80°C freezer and thawed at room temperature for 30min. A 
225µl volume of CM was added to an equal volume of PRP and incubated for three hours 
at room temperature (RT) to determine the effect of CM from lymphoma cells on 
healthy platelets. Control samples contained 225μL PRP and 225μL fresh RPMI media.  
6.2.4 Treating platelets with IL-6 and TNF-α 
As many cancer cells (including lymphoma cells) secrete high levels of IL-6 and TNF-α 
(Hsu et al., 1993), it was proposed that these cytokines, present in the CM, could affect 
platelet aggregation. Therefore, PRP from healthy subjects was incubated with different 
concentrations of IL-6 or TNF-α (Invitrogen, UK).  The same concentrations for both 
cytokines was used (1000,100,10,1,0.1 and 0ng/ml). A 400µl volume of PRP was 
incubated with 50µl of the relevant cytokine at RT for 3 hours. LTA was performed using 
ADP or Collagen as described in section 2.7. The control in this experiment was 
incubating 400μl of PRP with 50μL tyrodes buffer prior to LTA. 
6.2.5 Light transmission aggregometry (LTA)  
LTA was performed as described in section 2.7. Briefly, 450µl of PRP-CM samples or 
cytokine-treated PRP samples where stimulated with 50µl of ADP or Collagen used at 
10µM and 2µg/ml respectively. PPP was used as the LTA 100% control. 
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6.2.6 Flow cytometry 
Expression of the activation markers CD62P and activated fibrinogen receptor using 
anti-CD62P and PAC1 were was tested. PRP was incubated with CM or IL-6/TNFα as 
before but the volumes used for the testing in this methodology was different. An 80μL 
volume of PRP was incubated with 10μL cytokine at different concentrations (as above). 
Following incubation, 4μL fluorescence isothiocyanate (FITC)- PAC-1 and 4μL 
phycoerythrin (PE)-CD62P were added with 10μL ADP as the agonist. 100μL 
paraformaldehyde (PFA) 4% was also added to fix the cells followed by 300μL Dulbecco’s 
phosphate buffered saline (DPBS). Cells were the analysed immediately on a FACSVerse 
Flow Cytometer using BD FACSSuite software (Becton Dickinson, UK) 
 
6.2.7 Statistical Analysis 
GraphPad Prism version 5.0 was used for analyses. Statistical analysis was performed 
using one-way ANOVA with Dunnett’s post-hoc test. A significant result was represented 
as p < 0.05.  
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6.3 Results 
6.3.1 Effect of conditioned media on platelet aggregation 
6.3.1.1 Platelet aggregation Using ADP as the agonist  
Platelet rich plasma (PRP) was incubated with CM collected from L1236 cells incubated 
at varying cell densities for varying times. There was a difference in maximum platelet 
aggregation (MaxA) between PRP incubated with CM and the control samples when 
they were triggered by ADP. The representative aggregometry trace shows a decrease 
in aggregation from control (blue line) when PRP was treated with CM from cells 
cultured for varying times (24, 48 and 72 hours) (Fig. 6.1). Figure 6.2 shows that the 
decrease in aggregation was independent of culture time before CM collection or 
concentration of cells used for culture. 
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Figure 6.1  Representative Aggregometry Trace following incubation of PRP with 
CM from cultured L1236 cells - Blue: Control, Black: CM from 48h culture, Purple: 
CM from 72h Culture, Green: CM from 96h Culture. 
 
 
Figure 6.2 Platelet Aggregation in PRP from healthy individuals treated with CM 
from cells seeded at varying densities for varying times. Data is expressed at mean 
of two independent samples n=1. 
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6.3.1.2 Platelet aggregation using collagen as the agonist 
PRP incubated with CM was analysed by LTA as before but collagen was used as the 
agonist. This time only the effect of L1236 culture time was studied. Similarly to the 
results observed using ADP as the agonist, there was a significant decrease (P=0.002) in 
MaxA in platelets incubated with CM compared to the control sample following 
stimulation with collagen (Fig 6.3). The decrease in platelet aggregation was seen in all 
samples incubated with CM (Fig 6.4). 
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Figure 6.3  Representative Aggregometry Traces from a single participant. PRP was pre-
incubated for three hours with conditioned media (or tyrode’s buffer) collected from 1x106 
L1236 cells before stimulation with Collagen (1 µg/ml) for 5 minutes. Blue Line: Control, Black 
Line: 48h culture, Purple Line: 72h Culture. 
 
Figure 6.4  Maximum Platelet Aggregation in PRP from healthy individuals treated with CM 
from cells seeded at 1x106 cells/well for varying culture times. Data is presented as mean ± 
SEM of n=3.  Statistical analysis was performed using the one-way ANOVA with Dunnett’s post 
hoc test. Statistical differences are highlighted on the graph. *** Represents p<0.0001.  
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6.3.2 Effect of conditioned media on platelet activation  
6.3.2.1 Analysis of platelet activation using ADP as the agonist 
The activation status of healthy platelets following treatment with CM was assessed by 
analysis of PAC-1 binding to the activated fibrinogen receptor, and CD62P (P-selectin) 
expression. Representative flow cytometry histograms show the marked inhibition of 
platelet activation There was significant inhibition in ADP-induced platelet activation 
when platelet had been pre-treated with CM (Fig 6.5).  
 
The activation status was assessed following treatment with CM that had been collected 
from L1236 cells cultured at a range of cell concentrations (3x106, 4x106 and 5x106 
cells/ml) at a range of time points (24, 48, 72 and 96 hours). The collected CM was used 
to treat PRP from three independent donors, with each sample treated twice. The 
collective data demonstrated that the lymphoma secretome significantly inhibited 
platelet activation at all cell concentrations and all culture durations, evidenced by both 
a lower CD62P expression (Fig 6.6) and PAC-1 binding (Fig 6.7).   
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(A) (B) 
 
 
 
 
 
  
Figure 6.5 Representative FACS histograms for CD62P expression and PAC-1 expression, respectively, on 
untreated platelets (red) and platelets following 1-hour culture with conditioned media from 1x106 
cells/ml L-1236 cells (p<0.01) (green). Healthy platelets were stained n=3 by (A) PE-A anti-CD62P (B) 
FITC-A anti-PAC-1 for 20 minutes following stimulation with ADP (10 µM). The data represents 10 000 
events. 
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Figure 6.6 ADP-induced CD62P expression (% of control) in healthy platelets after 1-hour culture with 
conditioned media from (A) 3x106 cells/ml L-1236 cells (p<0.0001), (B) 4x106 cells/ml L-1236 cells 
(p<0.0001) (C) 5x106 cells/ml L-1236 cells (p=0.0001). Data is represented as mean + SEM. Data was 
produced from three donors, n=3. Statistical analysis was performed using the one-way ANOVA with 
Dunnett’s post-hoc test and significant differences are indicated. 
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Figure 6.7 ADP-induced PAC-1 binding (% of control) in healthy platelets after 1-hour culture with 
conditioned media from (A) 3x106 cells/ml L-1236 cells (p=0.0008) (B) 4x106 cells/ml L-1236 cells 
(p=0.0076) (C) 5x106 cells/ml L-1236 cells (p=0.0069). Data is represented as mean + SD. Data was 
produced from three donors (n=3). Statistical analysis was performed using the one-way ANOVA with 
Dunnett’s post-hoc test and significant differences are indicated. 
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6.3.2.2 Analysis of platelet activation using collagen as the agonist 
The activation status was assessed following treatment with CM that had been collected 
from L1236 cells cultured at 5x106 cells/ml at a range of time points (24, 48, 72 and 96 
hours). The collected CM was used to treat PRP from three independent donors, with 
each sample treated twice.  
 
Collagen-induced expression of CD62P significantly decreased when PRP was incubated 
with the lymphoma secretome that had been collected after 96 hours of culture (Fig 
6.8). Also, PAC-1 binding decreased significantly in samples incubated with the 
lymphoma secretome that had been collected after 72 or 96 hours (Fig 6.9). This 
illustrates the inhibitory effect of the secretome on platelet activation, and suggests a 
mechanism for bleeding tendencies observed in some  Lymphoma patients.  
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Figure 6.8 Collagen-induced CD62P expression (% of control) in healthy platelets after 1-
hour culture with conditioned media from 5x106 cells/ml, L-1236 cells (p=0.0001) 
collected after varying culture times. Data is represented as mean + SEM. Data was 
produced from three donors (n=3). Statistical analysis was performed using the one-way 
ANOVA with Dunnett’s post-hoc test and significant differences are indicated. **** 
represents P<0.0001. 
Figure 6.9 Collagen-induced PAC-1 binding (% of control) in healthy platelets after 1-hour culture with 
conditioned media from 5x106 cells/ml, L-1236 cells (p=0.0001) collected after varying culture times. 
Data is represented as mean + SEM. Data was produced from three donors (n=3). Statistical analysis was 
performed using the one-way ANOVA with Dunnett’s post-hoc test and significant differences are 
indicated. **** represents P<0.0001.  
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6.3.3 The Effect of IL-6 and TNF-α on Platelet Aggregation. 
IL-6 and TNFα are elevated in the serum of lymphoma patients and are secreted by 
lymphoma cells, including L1236 in-vitro. As there is significant inhibition in ADP- and 
collagen-stimulated MaxA of platelets incubated with CM from L1236, it was proposed 
that IL-6 and TNFα may be exerting this effect. So two different experiments were 
conducted treating PRP with IL-6 or TNFα and using ADP as the platelet agonist. 
 
6.3.3.1 Platelet Aggregometry Studies using ADP as the Agonist 
There was no significant difference in ADP-stimulated MaxA after treating platelets with 
different concentrations of IL-6 (Fig 6.10) or TNF-α (Fig 6.11), when compared with 
control (Tyrode’s buffer-treated) samples. The LTA traces show there is no difference in 
platelet aggregation, with the  maximum platelet aggregation at approximately the 
same level in CM-treated samples as the control sample aggregation (≈70% and 80% 
respectively).  
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(A) 
 
 
(B) 
 
 
  
Figure 6.10 (A) Representative Platelet aggregation trace from a single healthy participant, following 
treatment of PRP with different concentrations of IL-6 in a dose dependent manner, followed by 
stimulation with ADP (10 µM). Blue Line: Control, Black Line: 0.1ng/ml, Purple Line: 1.0 ng/ml, Green 
Line: 10ng/ml). (B) Collective data from three healthy participants (n=3). Data is represented as mean ± 
SEM. One-way ANOVA with Dunnett’s post-hoc test revealed no significant differences in MaxA (%) from 
control (tyrode’s buffer-treated platelets). 
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Figure 6.11 (A) Representative Platelet aggregation trace from a single healthy participant, following 
treatment of PRP with different concentrations of TNF-α in a dose dependent manner, followed by 
stimulation with ADP (10 µM). Blue Line: Control, Black Line: 0.1ng/ml, Purple Line: 1.0 ng/ml, Green 
Line: 10ng/ml). (B) Collective data from three healthy participants (n=3). Data is represented as mean ± 
SEM. One-way ANOVA with Dunnett’s post-hoc test revealed no significant differences in MaxA (%) from 
control (tyrode’s buffer-treated platelets). 
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6.3.4  Platelet Aggregometry Studies using Collagen as the Agonist 
In contrast to the results observed using ADP as the agonist, when stimulating IL-6- or 
TNF-α -treated PRP with collagen, there was a significant difference in aggregation when 
compared with control (Tyrode’s buffer-treated) samples. The significant difference was 
dose-dependent for both IL-6 (Fig 6.12) and TNF-α (Fig 6.13). 
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Figure 6.12 (A) Representative Platelet aggregation trace from a single healthy participant, following 
treatment of PRP with different concentrations of IL-6 in a dose dependent manner, followed by 
stimulation with Collagen (1 µg/ml). Blue Line: Control, Black Line: 0.1ng/ml, Purple Line: 1.0 ng/ml, 
Green Line: 10ng/ml). (B) Collective data from three healthy participants (n=3). Data is represented as 
mean ± SEM. One-way ANOVA with Dunnett’s post-hoc test revealed no significant differences in MaxA 
(%) from control (tyrode’s buffer-treated platelets). 
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(B) 
 
 
Figure 6.13 (A) Representative Platelet aggregation trace from a single healthy 
participant, following treatment of PRP with different concentrations of TNF-α in a 
dose dependent manner, followed by stimulation with Collagen (1 µg/ml). Blue Line: 
Control, Black Line: 0.1ng/ml, Purple Line: 1.0 ng/ml, Green Line: 10ng/ml). (B) 
Collective data from three healthy participants. Data is represented as mean ± SEM. 
One-way ANOVA with Dunnett’s post-hoc test revealed no significant differences in 
MaxA (%) from control (tyrode’s buffer-treated platelets). 
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6.3.5 Verification of IL-6/TNFα effects on collagen-induced platelet 
aggregation  
As platelet aggregation was not affected by IL-6 or TNF-α when ADP was used as the 
agonist, further confirmation was required that collagen-induced aggregation was 
affected by these cytokines. However, the results appeared inconsistent every time with 
every donor. Therefore, it was proposed that there may be a stability issue with the 
collagen itself that needed resolving. Rather than diluting the collagen to the required 
concentration (1mg/ml) in Tyrode’s solution, it was decided to add neat collagen directly 
to the sample at a 1:1000 ratio in PRP (final concentration of 1mg/ml). This prevented 
the collagen from forming aggregates in the Tyrode’s buffer and degrading.  
 
6.3.6 Repeating platelet aggregation following IL-6 and TNFα, using non-pre-
diluted collagen. 
There was no significant difference in platelet MaxA aggregation after repeating the 
experiments involving incubation of platelets with IL-6 and TNFα, and stimulating with 
non-pre-diluted collagen (Fig 6.14). Although platelet aggregation appeared to decrease 
when the platelets were incubated with 10 and 100ng/ml TNF- α, MaxA returned close 
to levels in the control samples when treated with 1000ng/ml. Furthermore, the platelet 
aggregation traces did not identify any difference between the control and treated 
samples with TNF- α and IL-6.  
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Figure 6.14 Representative aggregometry traces and dose response curves in response to TNF- α (A and B) and IL-6 (C and D), after stimulation with non-pre-
diluted collagen. For aggreometry traces, Blue: Control, Black: 0.1ng/ml, Purple: 1.0 ng/ml, Green 10ng/ml) (B &D) There was no significant  difference in Max 
platelet aggregation of incubated platelets with different concentration of IL- and TNF-α. statistical analysis was performed using the one-way ANOVA with 
Dunnett’s post hoc test. 
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6.3.7 Repeating platelet aggregation following L1236 CM, using non-pre-
diluted collagen. 
Re-testing collagen-induced platelet aggregation following incubation with CM was 
important to confirm that earlier results were significant and not due to collage 
instability. 
The results still showed significant differences between PRP incubated with with CM of 
L1236 and control samples, verifying the results seen earlier (Fig. 6.15). This shows that 
the tumour (specifically lynphoma) secreome has a significant effect on platelet 
aggregation which may be responsbile for the increased bleeding tendency often 
observed in the cancer setting.  
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Figure 6.15  Platelet aggregation following incubation with CM from L1236 cells, and stimulated 
with non-pre-diluted collagen. (A) Represenative aggregmetry trace (Blie: Control, Black: 48h 
Culture CM, Purple: 72h Culture CM, Green: 96h Culture CM). (B) Collective data fro three 
healthy participants. Data is represented as mean ± SEM. One-way ANOVA with Dunnett’s post-
hoc test revealed no signifciant differnce in MaxA (%) from control (Tyrode’s buffer-trested 
platelets). 
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6.3.7.1 Repeating platelet activation following L1236 CM using non-pre-diluted 
collagen 
Collagen-induced CD62P expression was significantly lower following incubation with 
CM collected after 96 hour culture of L1236 cells (Fig 6.16) when compared to 
expression in control samples. Also, Collagen-induced PAC1 binding was also 
significantly lower following incubation with CM collected after 72 and 96 hour culture 
of L1236 cells (Fig 6.17). These data illustrate the inhibitory effect of the tumour 
(specifically lymphoma) secretome on platelet activation, which again, may be 
responsbile for the increased bleeding tendency often observed in the cancer setting.  
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Figure 6.17 Collagen-induced CD62P expression (% of control) in healthy platelets 
after 1-hour culture with conditioned media from 5x106 cells/ml, L-1236 cells 
(p=0.0001) collected after varying culture times. Data is represented as mean + 
SEM. Data was produced from three donors (n=3). Statistical analysis was 
performed using the one-way ANOVA with Dunnett’s post-hoc test and 
significant differences are indicated. ** represents P<0.01, *** represents 
p<0.001. 
  
Figure 6.16 Collagen-induced PAC-1 expression (% of control) in healthy platelets 
after 1-hour culture with conditioned media from 5x106 cells/ml, L-1236 cells 
(p=0.0001) collected after varying culture times. Data is represented as mean + SEM. 
Data was produced from three donors (n=3). Statistical analysis was performed 
using the one-way ANOVA with Dunnett’s post-hoc test and significant differences 
are indicated. **** represents P<0.0001 
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6.3.8  Discussion 
Platelets have been shown to sequester tumour-derived proteins that are secreted from 
cancer cells such as lymphoma cells into the microenvironment (Klement et al., 2009; 
Nilsson et al., 2011; Kerr et al., 2010). The effect of these proteins on the haemostatic 
function of platelets has, so far not been investigated. 
 
The initial data from this project showed that incubating healthy platelets with a tumour 
secretome (conditioned media from Hodgkin Lymphoma cells) significantly inhibits 
platelet aggregation and activation potential, upon stimulation with either ADP or 
collagen (Fig 6.1-6.9). Platelets were inhibited after just three hours of CM-treatment, 
and the effect was observed irrespective of time of lymphoma cell culture or L1236 
seeding density. This would account for the increased risk of bleeding seen in a 
proportion of lymphoma patients. 
 
There are a large number of factors known to be released by lymphoma cells in culture 
and many of these, including IL-6, TNFα, IL-5, IL-9, IL-2 and TGFβ1 are also elevated in 
the serum of lymphoma patients (Hsu et al., 1993). We focused on IL-6 and TNFα, as 
both have been shown to be elevated, not only in lymphoma patients, but in many other 
cancer settings. Initial results showed neither IL-6 nor TNFα had a significant effect on 
aggregation or activation (CD62P and PAC1 binding) in response to ADP (Fig 6.10, 6.11), 
while aggregation and activation in response to collagen (Fig 6.12, 6.13) was significantly 
inhibited. However, the massive heterogeneity between samples warranted 
investigation into the stability of the collagen being used as an agonist. Using non-pre-
diluted collagen (i.e. collagen that was not diluted in Tyrodes buffer to the required 
  171 
2µg/ml prior to use) in a repeat set of experiments proved that neither IL-6 nor TNFα 
significantly affected aggregation or in response to collagen. 
However, when the effects of the CM from the L1236 cells were retested using non-pre-
diluted collagen a significant effect on both aggregation and activation (CD62P and PAC1 
binding) was still observed (Fig 6.15-6.17).  Therefore, other factors within the 
lymphoma secretome are responsible for this inhibition on platelet function. 
 
A study by Nilsson et al. (2013) reported that platelets contain tumour-derived RNA 
molecules that they propose can be used in biomarker analysis. Assessment of platelet 
function has not been studied in this context and therefore could be the cause of the 
inhibition of aggregation and activation potential observed in this study following 
incubation with the lymphoma secretome. Dysfunctional expression of miRNAs is a 
common feature of malignancy (Lawrie et al., 2007).   
 
The expression level of some miRNAs in the serum of lymphoma patients is dysregulated  
(Fang et al., 2012). Additionally it has been found that in HL cell lines there is a significant 
overexpression of miR-21, miR-15b and miR-16 and down regulation of others such as 
miR-150 (Gibcus et al., 2009). It is proposed that in-vivo, lymphoma cells may export 
miRNAs into the extracellular milieu, which may then travel from the lymph node to the 
peripheral blood to be a target for platelet uptake. Despite platelets being anucleated 
cells, they are capable of post-transcriptional gene regulation, owing to the messenger 
ribonucleic acid (mRNA) from their parent megakaryocyte during platelet production 
(Stakos et al., 2013; Nilsson et al., 2011; Hsu et al., 1993) Therefore, the uptake of 
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tumour-derived miRNA by platelets may have an effect on mRNA translation and 
therefore protein synthesis in the platelet (Soslau et al., 1997).  
 
Interest in tumour-derived microparticles (MPs) has recently grown, with evidence that 
MPs can ‘deliver’ chemoresistance genes from one cancer cell to another (Martins et al., 
2013). Despite their small size, MPs contain a very concentrated set of cytokines, 
signalling proteins, mRNA, and microRNA which originate from the cell they were shed 
from (Martins et al., 2013). The possibility of lymphoma-derived MPs causing changes 
to platelet function is not inconceivable and provides justification for studying this 
aspect in future work. 
 
Collagen has been proposed to be the strongest agonist of platelet aggregation. When 
used to stimulate platelets in the current study, aggregation and activation levels were 
significant in healthy platelets. Initial data showed that incubation of the healthy 
platelets with either the lymphoma secretome or either one of the recombinant 
cytokines IL-6 or TNFα resulted in a significant inhibition of collagen-induced 
aggregation and activation. However, re-running untreated samples at the end of the 
experiments proved that decreases in aggregation were due to instability of the collagen 
solution during the experiment. The collagen is supplied as a stock solution of 1mg/ml 
but must be diluted in Tyrode’s solution to a working concentration of 20g/ml. When 
50µl of this is added to a 450µl volume of PRP, this adjusts the final concentration to 
2g/ml. This is a standard protocol used by many platelet laboratories worldwide. The 
collagen begins to form aggregates within the Tyrode’s solution and stability 
experiments involving repeated analysis of PRP over time showed significant loss of 
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effect, even when storing the solution on ice. By adding 1µl of stock collagen directly to 
499µl PRP, the stability problem was resolved. Further experiments using the new 
method showed that collagen-induced aggregation is indeed inhibited by the lymphoma 
secretome, but not be either recombinant IL-6 or TNFα. 
 
Interaction between platelets and collagen is important in the study of platelet 
activation, where collagen binds to platelet receptors directly or indirectly with α2β1 and 
αIIBβ3 (via VWF). This binding is needed for high affinity confirmation in response to 
inside out signalling that uses GPVI receptor on platelets to provide more stable 
adhesion. However, different factors may influence this, such as the type of collagen in 
terms of preparation and species source of collagen (Nieswandt and Watson, 2003).  
 
There are more than 20 types of collagen in humans and 9 of them have been identified 
to be expressed on the vessel wall, I, II, IV, V, VI, VII, VIII, XII, XIII and XIV. The major 
component of extracellular matrix is fibrillar type III collagen and I, which are used 
commonly in platelet studies. This type consists of chains that contain 1000 amino acids 
flanked by “short non-helical N-and C- terminal telopentide extension” (Nieswandt and 
Watson, 2003). This monomeric cross-linked structure forms fibrillar collagen, which 
needs specific preparation to use in-vivo, and in-vitro to stimulate platelets. However, 
the complicated structure may lead to stability issues (Nieswandt and Watson, 2003).  
In this study fibril type I collagen, which is sourced from equine tendons, has been used 
which also has a complicated structure, as evidenced from the stability issues seen here.  
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In contrast to the results presented in this chapter, Soslau et al (1996) demonstrated 
significant stimulation of collagen-induced platelet aggregation following incubation 
with IL-6, while a small inhibition of aggregation was observed following incubation with 
TNF-α (Soslau et al., 1996). The reason for the opposing results, in terms of IL-6 between 
the present study and Saslow et al. remains to be fully determined but could be due to 
differences in post-transcriptional gene regulation within the sample population. 
However, no haemostatic abnormality has been reported in patients who have received 
IL-6 in clinical trials (Oleksowicz et al., 1994), although this direct relationship has not 
been the focus of any investigation.  
 
Another study has shown significant increases in platelet aggregation when platelets 
were incubated with TNF-α and triggered by collagen (Pignatelli et al., 2005). This is in 
contrast to the results presented here. The experimental protocol did however 
difference between the two studies; Pignatelli et al. (2005) incubated the TNFα-treated 
platelets at 370C for 15 minutes prior to inducing aggregation by collagen, while in the 
present study, platelets were incubated at room temperature. P75, a platelet-specific 
receptor for TNF-α (Bar et al., 1997) may be more stable at 370C, increasing its effect on 
platelet function.  
 
The data reported here are based upon low donor numbers and cannot be used to 
provide definitive conclusions. However, there are similarities with our work and some 
of the work in the literature especially when considering ADP-induced platelet 
aggregation following recombinant cytokine treatment (Soslau et al., 1997; Pignatelli et 
al., 2005). Another limitation in this study is that only two platelet agonists, collagen and 
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ADP have been used. Further study needs to assess whether aggregation/activation in 
response to alternative agonists such as Thrombin, Epinephrine and Arachidonic acid is 
also affected by secretome factors (Pignatelli et al., 2005).  
 
A study by Leslie et al. (1994) has shown a significant increase in ADP-induced platelet 
aggregation after incubating platelets with IL-6. The disparity between this result and 
the results presented in the current chapter could be explained by contamination of PRP 
by leukocytes; IL-6 has been proposed to be involved in platelet aggregation through an 
alternative pathway, indirectly through mononuclear cells. These mononuclear cells 
express the IL-6 receptor and its activation leads to indirect activation and secretion of 
platelet activation agonists by the mononuclear cells themselves (Leslie et al., 1994). It 
is therefore imperative to ensure minimal leukocyte contamination in PRP. 
 
It has been proposed that cytokines themselves may act as direct platelet agonists if 
added at the start of aggregation analysis, however, no change in platelet function was 
seen when this was tested (data not shown). This has been supported by Pignatelli et al 
(2005) who used 40pg/ml of TNF-α as the agonist for platelet aggregation and found no 
difference in platelet aggregation. Yet, alternative studies have reported small agonist 
activities for TNFα (Soslau et al., 1997). Differences in mRNA and miRNA profiles 
between donors used in these studies could account for differences in response, as post-
transcriptional gene regulation in platelets has been shown to be extremely important 
in platelet behaviour. Incubation temperature and cytokine concentration also vary 
between these published studies (Bar et al., 1997; Pignatelli et al., 2005). 
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In-vitro studies of this nature present difficulties in recreating the in-vivo 
microenvironmental interactions which may be key to generating the changes in 
haemostatic function (Hsu et al., 1993). For example, platelets release some cytokines, 
which are proposed to act in concert with other cytokines released from additional cells 
within the microenvironment, to modulate haemostasis and thrombosis differentially 
dependent on the site of injury (Soslau et al., 1997). Therefore, the method used so far 
has its drawbacks. Whole blood aggregometry may have provided a more accurate 
assessment of the aggregation in this setting, to determine if the presence of other 
blood components exacerbates/amplifies effects seen in PRP.  
 
In conclusion, Although the secretome of HL cell line L1236 significantly inhibits platelet 
aggregation and activation, direct treatment with IL-6 and TNFα which are reported to 
be major factors present in the secretome have no effect. Future work in this area 
should aim to fully characterise the factors responsible for such as strong inhibitory 
action on platelet function. 
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7 Chapter 7: Conclusion and future work. 
 
7.1 Conclusion  
This work tested the anti-platelet activity of six novel thienopyridine derivatives with the 
aim of identifying new compounds that can be taken forward for further clinical 
development and used as alternatives to current anti-platelet therapies. Although a 
number of anti-platelet therapies are currently in clinical use, the heterogeneity 
amongst patients in terms of response to these agents and variability in side effects 
warrants continued identification and refinement of alternative compounds. 
 
The first experimental chapter demonstrated that all six novel compounds were able to 
inhibit ADP-stimulated platelet aggregation (assessed by LTA), platelet activation 
(assessed by CD62P expression, PAC-1 binding and PLT-LEUK aggregate formation), and 
were able to provide an additive effect when used in combination with Aspirin. 
Compounds DJ0199, DJ0171 and DJ0097 appeared to stand out as the most effective 
compounds. 
 
The second experimental chapter demonstrated the ability of the compounds to 
maintain VASP phosphorylation in ADP-stimulated platelets, further proving the 
inhibitory action of these compounds. Again, DJ0199, DJ0171 and DJ0097 appeared to 
be the most effective at inhibiting platelet activity. Work also attempted to determine 
other signalling pathways affected by these compounds, but could not find consistent 
effects on cPLA2, PLCγ2 or Akt.  
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The third experimental chapter focused on the effects of these compounds on 
endothelial cells, highlighting the significance of P2Y12 inhibition on global haemostasis. 
The chapter demonstrated that all compounds were able to inhibit ADP-stimulated 
expression of CD62P, CD62E and VCAM-1 expression on HUVEC cells, but the most 
successful compounds appeared to be DJ0199 and DJ0171. 
 
Taken together, the results provide justification for pursing the development of DJ0199 
and DJ0171 (and possibly DJ0097) and also show that these compounds may also be 
used in the setting of endothelial dysfunction. 
 
Finally, the work presented in chapter 6 focused on the immunological aspect of platelet 
biology and was able to show that platelet function can also be significantly affected by 
the tumour cell secretome. Platelet activation and aggregation was inhibited following 
incubation of platelets with conditioned media from Lymphoma cell lines. The results 
support data in the literature that describe the ability of platelets to sequester proteins 
from the microenvironment, and help to explain the increased bleeding tendency seen 
in a proportion of cancer patients.   
 
7.2 Future work 
The work focused on the use of these novel thienopyridines in platelets obtained from 
healthy patients. Although these platelets were stimulated with ADP following 
treatment with the novel compounds to mimic hyperactivity, future work should focus 
on obtaining platelets from patients with platelet hyperactivity. Patients with ACS, or 
those immediately following MI or stroke, but before being administered with a loading 
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dose of clopidogrel/ticagrelor would provide the ideal study setting. This would allow 
determination of the ability of these novel compounds to inhibit the activity of platelets 
with an inherently elevated baseline activation status. An additional follow on to this 
would be to obtain blood samples from clopidogrel-non-responders and test the efficacy 
of the novel derivatives. This would evaluate the benefits of these compounds in 
patients who cannot be treated with the mainstream treatment regime. 
 
The work presented in this thesis worked on platelets in a static environment – i.e. the 
PRP was treated in tubes with the relevant compounds and incubated for 30 mins before 
platelet stimulation and assessment of activation/aggregation. Further work would 
focus on the activation and aggregation of platelets treated with these compounds 
under a flow system that mimics physiological blood flow. Pre-treated platelets can be 
perfused over a surface coated with a platelet agonists and the adhesion of platelets to 
the agonist-coated surface following the flow assay can be assessed by epifluorescence 
microscopy  (Schulz et al., 2009; HEEMSKERK et al., 2011). Another useful adaptation of 
this assay could be a co-culture system of platelet and endothelial cells. Instead of 
coating a surface within the flow system with an agonist, the surface could be coated 
with a monolayer of HUVECs  (Terrisse et al., 2010). The thienopyridine-treated platelets 
would then be perfused through the system, stimulated with ADP and then their 
adhesion to the endothelaial layer would be assessed by epifluorescence microscopy. 
 
The pilot data presented in chapter 5, demonstrating the inhibitory effects of these 
compounds on endothelial cells, should be validated by analysing CD62P, CD62E, VCAM-
1 and ICAM-1 in ADP-stimulated HUVECs by flow cytometry and also western blotting. 
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The flow cytometry would provide quantitative data that can be statistically analysed to 
determine the most effective novel derivative in this setting. Furthermore, as ADP has 
been reported to stimulate migration of HUVEC cells via the ERK1/2 pathway, analysis 
of the phosphorylation status of ERK1/2 kinases following thienopyridine treatment 
would also be useful to explore. 
 
With regards to platelet signalling pathways affected by these compounds, western 
blotting proved difficult to anlyse these events that were occurring within microseconds 
of agonist treatment. Again, real-time flow cytometry on the Accuri C6 next generation 
flow cytometry would be a more effective method for assessing signal transduction in 
this setting. Further, expression of PLCβ would be a useful addition to the testing panel, 
due to its major role in Gq-coupled GPCRs including P2Y1 (alternative ADP receptor) 
(Szumilo and Rahden-Staron, 2008). 
 
Neither IL-6 nor TNFα were found to significantly affect ADP-mediated or collagen-
mediated activation/aggregation, despite the strong effect of the lymphoma cell 
secretome. Further work must characterise the factors within this secretome that are 
acting to inhibit platelet function. This would involve multiplex ELISA or cytometric Bead 
Array to characterise the exact cytokine profile of the secretome. 
 
8  
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